A PD-1 / PD-L1 inhibitor and its preparation method and use
By preparing and applying small molecule compounds with specific structures to inhibit the PD-1/PD-L1 signaling pathway, the problems of high cost and side effects of existing monoclonal antibodies have been solved, providing a more economical and safer tumor immunotherapy option.
Patent Information
- Application Number
- CN202180006127.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-01-21
- Filing Date
- 2021-01-21
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2041-01-21
AI Technical Summary
Existing PD-1/PD-L1 blockers are mainly monoclonal antibodies, which have high research and development costs and immunogenic side effects. Small molecule inhibitors have not yet been fully developed.
A small molecule compound that inhibits PD-1/PD-L1 interaction and its preparation method are provided. The compound is used to prepare a pharmaceutical composition by synthesizing a compound of a specific structural formula (I) and its stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts.
It achieves effective inhibition of the PD-1/PD-L1 signaling pathway, has potential therapeutic effects, reduces research and development costs, and reduces immune side effects.
Smart Images

Figure FDA0005086711330000011 
Figure FDA0005086711330000012 
Figure FDA0005086711330000013
Abstract
Description
[0001] This application claims the priority of the Chinese patent application filed with the China Patent Office on January 21, 2020, with application number 202010070965.3 and invention name “A PD-1 / PD-L1 inhibitor, preparation method and use thereof”, the entire contents of which are incorporated by reference into this application. Technical Field
[0002] The present invention belongs to the field of medicine and relates to a small molecule compound capable of inhibiting PD-1 / PD-L1 activity, a preparation method thereof, a pharmaceutical composition containing the compound, and applications thereof in medicine. Background Art
[0003] Cancer is one of the diseases that seriously threaten human health. Cancer prevention and treatment has become a very important public health issue. Along with surgical treatment, radiotherapy and chemotherapy, tumor immunotherapy, as one of the four major tumor treatment methods, is currently considered to be a very promising tumor treatment method. Immune checkpoint inhibitors are a hot research direction in this field and have made significant clinical research progress, providing a new weapon to fight cancer. Today, PD-1 / PD-L1 is one of the most popular immune checkpoints.
[0004] PD-1 (CD279) programmed death receptor 1 is an important immunosuppressive molecule; PD-1 is composed of 288 amino acids and belongs to the immunoglobulin CD28 superfamily. It is expressed on the surface of various immune cells such as activated T cells, B cells, natural killer (NK) cells and antigen-presenting cells, and its expression is upregulated on the surface of activated T cells in tumor patients. Its corresponding receptor PD-L1 (B7-H1, CD274) is mainly expressed in a variety of tumor cells, T cells, APCs and non-hematopoietic cells. The interaction between PD-1 and PD-L1 inhibits T cell activation, which is essential for maintaining normal collective immune tolerance. The tumor microenvironment in the body induces infiltrating T cells to highly express PD-1 molecules, and tumor cells to highly express PD-L1 and PD-L2, resulting in continuous activation of the PD-1 / PD-L1 signaling pathway in the tumor microenvironment, inhibition of T cell function, and immune escape of tumor cells.
[0005] Currently, several antibodies that block this signaling pathway have been approved, and multiple studies have confirmed that these antibodies are effective in a variety of tumors, such as melanoma, non-small cell lung cancer, renal cell carcinoma, gastric cancer, bladder cancer, and Hodgkin's lymphoma.
[0006] In summary, blockers of the PD-1 / PD-L1 / PD-L2 signaling pathway have achieved gratifying therapeutic effects in clinical tumor immunotherapy. Although monoclonal antibodies targeting some cancers have been successfully developed, their R&D costs are high, they are unstable, and have potential immunogenic side effects. Small molecule inhibitors acting on PD-1 / PD-L1 have received increasing attention.
[0007] The present invention provides a compound of the general structural formula (I) having the ability to inhibit PD-1 / PD-L1 interaction, as well as stereoisomers and pharmaceutically acceptable salts thereof, a preparation method thereof, a pharmaceutical composition thereof, and use thereof in drugs for preventing and treating diseases associated with the PD-1 / PD-L1 signaling pathway. Summary of the invention
[0008] The object of the present invention is to provide a compound represented by general formula (I), and their tautomers, enantiomers, diastereomers, racemates and pharmaceutically acceptable salts.
[0009] in
[0010] X 1 CR 2 , X 2 C, X 3 is C;
[0011] X 1 N, X 2 C, X 3 is C;
[0012] X 1 CR 2 , X 2 C, X 3 is N;
[0013] X 1 CR 2 , X 2 N, X 3 is C; or
[0014] X 1 CR 2 , X 2 N, X 3 is N;
[0015] R 0 NR a R 6 or -NR a C(O)R 6 ;
[0016] R 1 , R 3 and R4 are independently hydrogen, halogen or C 1-6 alkyl;
[0017] R 2 is hydrogen or C 1-6 alkyl;
[0018] R 5 C 5-12 Fused heterobicyclic group, -NR b R 7 or -NR b C(O)R 7 , where the C 5-12 The hydrogen atoms of the fused heterobicyclic group are independently optionally replaced by R d replace;
[0019] R 6 C 3-7 Heterocycloalkyl, C 3-9 Heteroaryl, C 6-12 Fused bicyclic or C 5-12 A fused heterobicyclic group, each R 6 The hydrogen atoms on the e replace;
[0020] R 7 C 3-7 Heterocycloalkyl, C 3-9 Heteroaryl, C 6-12 Fused bicyclic group, C 5-12 A fused heterobicyclic group, each R 7 The hydrogen atoms on the f replace;
[0021] R a and R b are independently hydrogen, -CH3 or -CH(CH3)2;
[0022] R d are independently halogen, cyano, C 1-6 Alkyl, C 3-7 Heterocycloalkyl or -methylene-C 3-7 Heterocycloalkyl, wherein the C 1-6 Alkyl, C 3-7 Heterocycloalkyl, -methylene-C 3-7 Heterocycloalkyl may be substituted with -CH3, -OH, -COOH, -COOCH3;
[0023] R e and R f are independently hydrogen, C 1-6 Alkyl, -(CH2) n -OH, -(CH2)n -NH2, -(CH2) n -NH-(CH2) n -CH3, -O-CH3, C 3-6 Cycloalkyl, C 3-7 Heterocycloalkyl, -methylene-C 3-7 Heterocycloalkyl or C 6-10 Aryl, wherein the C 1-6 Alkyl, -(CH2) n -OH, -(CH2) n -NH2, -(CH2) n -NH-(CH2) n -CH3、C 3-6 Cycloalkyl, C 3-7 Heterocycloalkyl, -methylene-C 3-7 Heterocycloalkyl, C 6-10 The aromatic group can be R j replace;
[0024] R j Halogen, hydroxyl, -NH2, C 1-6 Alkyl, -COOH, -COOCH3, -(CH2) n -OH, -(CH2) n -NH-CH3, -(CH2) n -O-CH3 or -(CH2) n -NH-C(O)-CH3;
[0025] n is 0, 1 or 2.
[0026] Preferably, in the compound represented by general formula (I),
[0027] R 0 For-NR a R 6 or -NR a -C(O)-R 6 ;
[0028] R 1 , R 3 and R 4 are independently -H, -F, -Cl or -CH3;
[0029] R 5 For-NR b R 7 、-NR b -C(O)-R 7 ,
[0030] R 6for
[0031] R a and R b are independently -H, -CH3 or -CH(CH3)2;
[0032] R d are independently -CH(CH3)2,
[0033] R e and R f are independently -H, -CH3, -CH2CH3, -CH(CH3)2, -CH2CH(CH3)OH, -CH2CH(OH)CH3,
[0034] More preferably, in the compound represented by general formula (I),
[0035] R 0 -NH-C(O)-R 6 、-NH-R 6 、-N(CH3)-C(O)-R 6 or -N(CH(CH3)2)-C(O)-R 6 ;
[0036] R 5 -NH-C(O)-R 7 、-NH-R 7 、-N(CH3)-C(O)-R 7 、-N(CH(CH3)2)-C(O)-R 7 ,
[0037] Preferably, in the compound represented by general formula (I),
[0038] X 1 CR 2 , X 2 C, X 3 is C;
[0039] R 0 -NH-C(O)-R 6 or -NH-R 6 ;
[0040] R 1 is -Cl or -CH3;
[0041] R 2 is -H;
[0042] R 3 is -Cl or -CH3;
[0043] R 4 is -H;
[0044] R 5 -NH-C(O)-R 7 ,
[0045] R 6 for
[0046] R e -H, -CH3, -CH2CH(CH3)OH,
[0047] R f -CH3,
[0048] Preferably, in the compound represented by general formula (I),
[0049] X 1 N, X 2 C, X 3 is C;
[0050] R 0 -NH-C(O)-R 6 or -NH-R 6 ;
[0051] R 1 is -CH3;
[0052] R 3 is -Cl or -CH3;
[0053] R 4 is -H or -CH3;
[0054] R 5 -NH-C(O)-R 7 、-NH-R 7 ,
[0055] R 6 for
[0056] R 7 for
[0057] R eis -H, -CH3, -CH2CH3, -CH(CH3)2, -CH2CH(CH3)OH or
[0058] R f is -CH3, -CH2CH3, -CH(CH3)2, -CH2CH(CH3)OH, -CH2CH(OH)CH3,
[0059] Preferably, in the compound represented by general formula (I),
[0060] X 1 CR 2 , X 2 C, X 3 is N;
[0061] R 0 -NH-C(O)-R 6 ;
[0062] R 1 is -Cl or -CH3;
[0063] R 2 is -H;
[0064] R 3 is -H, -Cl or -CH3;
[0065] R 4 is -H;
[0066] R 5 -NH-C(O)-R 7 ;
[0067] R 6 for
[0068] R 7 for
[0069] R e is -CH3 or -CH2CH(CH3)OH;
[0070] R f It is -CH3 or -CH2CH(CH3)OH.
[0071] Preferably, in the compound represented by general formula (I),
[0072] X 1 CR 2 , X 2 N, X 3 is C;
[0073] R 0 -NH-C(O)-R 6 、-N(CH3)-C(O)-R 6 or -N(CH(CH3)2)-C(O)-R 6 ;
[0074] R 1 is -Cl or -CH3;
[0075] R 2 is -H, -F or -Cl;
[0076] R 3 is -Cl or -CH3;
[0077] R 4 is -H;
[0078] R 5 -NH-C(O)-R 7 、-N(CH3)-C(O)-R 7 or -N(CH(CH3)2)-C(O)-R 7 ;
[0079] R 6 for
[0080] R 7 for
[0081] R e is -CH3 or -CH2CH(CH3)OH;
[0082] R f It is -CH3.
[0083] Preferably, in the compound represented by general formula (I),
[0084] X 1 CR 2 , X 2 N, X 3 is N;
[0085] R 0 -NH-C(O)-R 6 ;
[0086] R 1 is -Cl or -CH3;
[0087] R 2 is -H;
[0088] R 3 is -Cl or -CH3;
[0089] R 4 is -H;
[0090] R 5 -NH-C(O)-R 7 ;
[0091] R 6 for
[0092] R 7 for
[0093] R e is -CH3 or -CH2CH(CH3)OH;
[0094] R f It is -CH3 or -CH2CH(CH3)OH.
[0095] More preferably, the compound represented by general formula (I) is selected from:
[0096] N-(2-chloro-3′-(4-(((2-hydroxyethyl)amino)methyl)-1-methyl-1H-imidazole-2-carboxamido)-2′-methyl-[1,1′-biphenyl]-3-yl)-5-(((2-hydroxyethyl)amino)methyl)picolinamide;
[0097] N-(2′-chloro-3′-(5-((((2-hydroxyethyl)amino)methyl)picolinamido)-2-methyl-[1,1′-biphenyl]-3-yl)-4-(((2-hydroxyethyl)amino)methyl)thiazole-2-carboxamide;
[0098] (S)-N-(5-(3-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-4-methylpyridin-3-yl)-5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide;
[0099] (R)-1-(((2-(2,2′-dimethyl-3′-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido))-[1,1′-biphenyl]-3-yl) [5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid;
[0100] N-(5-(3-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-4-methylpyridin-3-yl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide;
[0101] N-(5-(3-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-4-methylpyridin-3-yl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide;
[0102] (R)-1-((2-(3′-((3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) oxazolo[5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid;
[0103] (R)-1-((7-chloro-2-(2-methyl-3-(4-methyl-5-(5-methyl-4,5,6,7-tetrahydrothiazol[5,4-c]pyridine-2-carboxamido)pyridin-3-yl)phenyl)benzo[d] oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0104] (R)-1-(((7-chloro-2-(4-methyl-5-(2-methyl-3-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)phenyl)pyridin-3-yl)benzo[d] oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0105] (R)-1-((2-(3′-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) oxazolo[5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid;
[0106] (R)-1-(((7-chloro-2-(5-(3-((3-(((((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2-methylphenyl)-4-methylpyridin-3-yl)benzo[d] (4-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid trifluoroacetate;
[0107] (R)-1-(((7-chloro-2-(5-(3-(5-((S)-2-hydroxypropyl))-1-methyl-4,5,6,7-tetrahydro-1H-imidazole[4,5-c]pyridine-2-carboxamide)-2-methylphenyl)-4-methylpyridin-3-yl)benzo[fd] oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0108] (R)-1-(((7-chloro-2-(5-(3-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-4-methylpyridin-3-yl)benzo[d] oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0109] (R)-1-((2-(3′-(5-((S)-2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazole[4,5-c]pyridine-2-carboxamido)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) [5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid;
[0110] N-(3-chloro-2-(3-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido))-2-methylphenyl)pyridin-4-yl)-1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide;
[0111] N-(3-(3-chloro-2-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide;
[0112] (R)-1-((2-(3′-((3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) (4,5-b]pyridin-5-yl)methyl)pyrrolidine-3-carboxylic acid trifluoroacetate;
[0113] (R)-1-((2-(2,2′-dimethyl-3′-(4,5,6,7-tetrahydrothiazolidine[5,4-c]pyridine-2-carboxamido)-[1,1′-biphenyl]-3-yl) [5,4-b]pyridin-6-yl)methyl]pyrrolidine-3-carboxylic acid trifluoroacetate;
[0114] (R)-1-(((7-chloro-2-(4-methyl-5-(2-methyl-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazole)[4,5-c]pyridine-2-carboxamido)phenyl)pyridin-3-yl)benzo[d] oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0115] (R)-1-(((7-chloro-2-(3-(5-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-4-methylpyridin-3-yl)-2-methylphenyl)benzo[d] 1-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid methyl ester;
[0116] (R)-1-(((7-chloro-2-(3-(5-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-4-methylpyridin-3-yl)-2-methylphenyl)benzo[d] oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0117] (R)-1-((2-(3′-(5-((S)-2-hydroxypropyl)4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) [5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid;
[0118] (S)-N-(5-(2-chloro-3-(1-methyl-5-(oxetan-3-yl)-4,5,6,7-tetrahydro-1H-imidazole [4,5-c] pyridine-2-carboxamide)phenyl)-4-methylpyridin-3-yl)-5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazole [4,5-c] pyridine-2-carboxamide;
[0119] (S)-N-(2-chloro-3-(5-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide)-4-methylpyridin-3-yl)phenyl)-5-isopropyl-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide;
[0120] (R)-1-(((7-cyano-2-(4-methyl-5-(2-methyl-3-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)phenyl)pyridin-3-yl)benzo[d] oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid;
[0121] N-(5-(2-chloro-3-(5-((S)-2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-4-methylpyridin-3-yl)-5-((S)-2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide;
[0122] N-(2-chloro-3-(5-(5-ethyl-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-4-methylpyridin-3-yl)phenyl)-5-ethyl-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide;
[0123] (R)-1-((2-(3′-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2)2′-dimethyl-[1,1′-biphenyl]-3-yl) oxazolo[5,4-c]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid;
[0124] (R)-1-((2-(3′-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) [5,4-c]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid;
[0125] (R)-1-(((7-chloro-2-(3-(5-(5-((S)-2-hydroxypropyl))-1-methyl-4,5,6,7-tetrahydro-1H-imidazole[4,5-c]pyridine-2-carboxamido)-4-methylpyridin-3-yl)-2-methylphenyl)benzo[d] oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid.
[0126] The compound represented by the general formula I can be prepared by the following scheme:
[0127] Scenario 1:
[0128]
[0129] Y1, Y2 and Y3 are N or C, wherein at least two of Y1, Y2 and Y3 are C atoms, or Y1 is CR, wherein R is halogen or -CN, and R is further preferably -Cl or -CN;
[0130] Y4 is fluorine, chlorine, bromine or iodine;
[0131] Compound (II-1) reacts with the corresponding arylamine (II-2) under alkaline conditions in the presence of a condensing agent to obtain compound (II-3). Compound (II-3) is cyclized under copper salt catalysis to obtain compound (II-4), and the copper salt used is preferably cuprous iodide, cuprous bromide, cuprous chloride, etc. Compound (II-4) is subjected to three steps of reduction, oxidation and reductive amination to obtain compound (II-7). Compound (II-7) reacts with diboric acid pinacol ester under heating and alkaline conditions in the presence of a catalyst to obtain compound (II-8). Compound (II-8) reacts with compound (II-9) under heating and alkaline conditions in the presence of a catalyst to obtain compound (I).
[0132] Compound (II-4) can also be synthesized by the following method:
[0133]
[0134] Compound (II-a) and (II-b) are directly heated to undergo a ring-closure reaction to obtain compound (II-4).
[0135] Scenario 2:
[0136]
[0137] Compound (III-1) reacts with the corresponding arylamine (III-2) under alkaline conditions in the presence of a condensing agent to obtain compound (III-3). Compound (III-3) is reduced with a reducing agent and then reacted with the corresponding acid (III-5) under alkaline conditions in the presence of a condensing agent to obtain compound (I).
[0138] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0139] Unless otherwise indicated, conventional methods within the technical scope of the art are used, such as mass spectrometry, NMR, IR and UV / VIS spectroscopy and pharmacological methods. Unless specifically defined, the terms used herein in the relevant descriptions of analytical chemistry, organic synthesis chemistry, and drugs and medicinal chemistry are known in the art. Standard techniques can be used in chemical synthesis, chemical analysis, drug preparation, preparation and delivery, and in the treatment of patients. For example, the instructions for use of the kit can be utilized by the manufacturer, or reactions and purification can be implemented according to methods well known in the art or the description of the present invention. Conventionally, the above-mentioned techniques and methods can be implemented according to conventional methods well known in the art, according to the description in a plurality of summaries and more specific documents cited and discussed in this specification.
[0140] When substituents are described by conventional chemical formulas written from left to right, the substituents also include chemically equivalent substituents that would result if the formula were written from right to left. For example, -CH2O- is equivalent to -OCH2-.
[0141] The section titles used in the present invention are only used for the purpose of organizing the articles and should not be interpreted as limitations on the subject matter. All documents or document portions cited in this application, including but not limited to patents, patent applications, articles, books, operating manuals and papers, are incorporated herein by reference in their entirety.
[0142] In the present invention, "optional" or "optionally" means that the event or situation described later may or may not occur, and the description includes both the occurrence and non-occurrence of the event or situation. For example, "optionally substituted aryl" means that aryl is substituted or unsubstituted, and the description includes both substituted aryl and unsubstituted aryl.
[0143] When used in reference to a specific recited numerical value, the term "about" means that the value may vary by no more than 1% from the recited value. For example, as used herein, the expression "about 100" includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0144] The term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of..." or "consisting of..."
[0145] The term "alkyl" in the present invention includes saturated aliphatic groups, including straight-chain alkyl groups (e.g., methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, etc.), branched-chain alkyl groups (e.g., isopropyl, tert-butyl, isobutyl, etc.), cycloalkyl groups (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and adamantyl), alkyl-substituted cycloalkyl groups, and cycloalkyl-substituted alkyl groups.
[0146] In certain embodiments, preferred cycloalkyl groups have 3-8 carbon atoms in their ring structure, and more preferably have 5 or 6 carbon atoms in their ring structure.
[0147] The term "C 1-6 The term "alkyl" includes alkyl groups containing 1 to 6 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, sec-pentyl or n-hexyl. 1-3 The term "alkyl" includes alkyl groups containing 1 to 3 carbon atoms, specifically methyl, ethyl, n-propyl and isopropyl.
[0148] Additionally, the term "alkyl" also includes "unsubstituted alkyl" and "substituted alkyl," the latter of which refers to alkyl groups in which the hydrogen on one or more carbons in the hydrocarbon backbone is replaced by a substituent. The substituents may include alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, hydroxycarbonyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, hydroxythiocarbonyl, sulfate, alkylsulfinyl, sulfonic acid, sulfamoyl, sulfonylamino, nitro, trifluoromethyl, cyano, azido, heterocyclic, alkylaryl or aromatic or heteroaromatic groups.
[0149] As used herein, "heterocycle" or "heterocyclic group" includes any ring structure (saturated, unsaturated or aromatic) containing at least one ring heteroatom (e.g., a nitrogen atom, an oxygen atom, or a sulfur atom). Heterocycles include heterocycloalkyl and heteroaryl. Examples of heterocyclic groups include, but are not limited to, furanyl, pyridazine, imidazolidinyl, imidazolinyl, imidazolyl, isoquinolinyl, thiazolyl, isothiazolyl ... Azolyl, methylenedioxyphenyl, morpholinyl, Oxazolidinyl, Azolyl, Oxazolyl, 1,2,3- Oxazolyl, 1,2,4- Oxazolyl, 1,2,5- Oxazolyl, 1,3,4- Oxazolyl, 1,2,4- oxadiazole 5(4H)-one, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, pyranyl, tetrahydropyran, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2H-pyrrolyl, pyrrolyl, tetrahydrofuranyl, tetrazolyl, thiazolyl, thienyl, tetrahydrothiophene, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, oxetane, azetidine.
[0150] The term "aryl" or "aromatic ring" includes 5- and 6-membered monocyclic aromatic groups which may contain 0-4 heteroatoms, such as benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, Azoles, Isopropylamine oxazole, pyridine, pyrazine, pyridazine and pyrimidine, etc.; in addition, the term "aryl" also includes polycyclic aromatic groups, such as tricyclic and bicyclic aromatic groups, such as naphthalene, benzoxazole, benzodiazole, benzothiazole, benzimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, naphthyridine, indole, benzofuran, purine, benzofuran, deazapurine or indolizine.
[0151] Aryl groups having heteroatoms independently selected from nitrogen, oxygen and sulfur, the nitrogen atoms being substituted or unsubstituted, the nitrogen and sulfur heteroatoms being optionally oxidized (i.e., N→O and S(O)), are also referred to as "aryl heterocycles", "heterocycles", "heteroaryls" or "heteroaromatic groups". p , wherein p=1 or 2), the total number of sulfur and oxygen atoms in the aromatic heterocyclic ring does not exceed 1.
[0152] Typical heteroaryl groups include 2- or 3-thienyl; 2- or 3-furanyl; 2- or 3-pyrrolyl; 2-, 4- or 5-imidazolyl; 3-, 4- or 5-pyrazolyl; 2-, 4- or 5-thiazolyl; 3-, 4- or 5-isothiazolyl; 2-, 4- or 5-oxazolyl; 3-, 4- or 5-isoxazolyl; 3- or 5-1,2,4-triazolyl; 4- or 5-1,2,3-triazolyl; tetrazolyl; 2-, 3- or 4-pyridinyl; 3- or 4-pyridazinyl; 3-, 4- or 5-pyrazinyl; 2-pyrazinyl; 2-, 4- or 5-pyrimidinyl.
[0153] The aromatic ring of "aryl" or "heteroaryl" can be substituted at one or more ring positions with substituents as described above, such as halogen, hydroxy, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, hydroxycarbonyl, alkylcarbonyl, alkylaminocarbonyl, arylalkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, arylalkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, phosphate, phosphonate, cyano, amino (including alkylamino, dialkylamino) and alkylamino. The invention also includes a moiety comprising a cyclopentyl group, ...
[0154] The terms "fused bicyclic ring" and "fused bicyclic group" are used interchangeably herein to refer to a monovalent or multivalent saturated or partially unsaturated bridged ring system, which refers to a bicyclic ring system. The term "bridged ring" refers to any two rings that share two atoms that are directly or indirectly connected.
[0155] The term "fused heterobicyclic ring" means a saturated or partially unsaturated fused ring system, and at least one ring system contains one or more heteroatoms, wherein each ring system contains 3-7 ring members, i.e. contains 1-6 carbon atoms and 1-3 heteroatoms selected from N, O, P, S, wherein S or P is optionally substituted by one or more oxygen atoms to obtain groups such as SO, SO2, PO, PO2, and the fused heterobicyclic group can be substituted or unsubstituted.
[0156] The term "C 6-10 The term "aryl" includes aromatic groups containing 6 to 10 carbon atoms.
[0157] The term "C 1-9 The term "heteroaryl" includes heteroaryl groups containing 1 to 9 carbon atoms.
[0158] The term "C 6-12 The term "fused bicyclic group" includes fused bicyclic groups containing 6 to 12 carbon atoms.
[0159] The term "C 5-12 "Fused heterobicyclyl" includes heterobicyclyls containing from 5 to 12 carbon atoms. The term "alkenyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one double bond.
[0160] For example, the term "alkenyl" includes straight chain alkenyl (e.g., vinyl, propenyl, butenyl, pentenyl, hexenyl, heptenyl, octenyl, nonenyl, decenyl, etc.), branched alkenyl, cycloalkenyl (e.g., cyclopropenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl), alkyl or alkenyl substituted cycloalkenyl, and cycloalkyl or cycloalkenyl substituted alkenyl. The term "alkenyl" also includes alkenyl containing oxygen, nitrogen, sulfur or phosphorus atoms replacing one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight or branched alkenyl has 6 or fewer carbon atoms in its backbone (e.g., C 2-6 Straight chain alkenyl, C 3-6 Term C 2-6 The alkene group includes an alkenyl group containing 2 to 6 carbon atoms.
[0161] Additionally, the term "alkenyl" includes "unsubstituted alkenyls" and "substituted alkenyls," the latter of which refers to alkenyls in which a hydrogen on one or more carbons in the hydrocarbon backbone is replaced with a substituent. The substituents may include, for example, alkyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, hydroxycarbonyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, phosphonate, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, hydroxythiocarbonyl, sulfate, alkylsulfinyl, sulfonic acid, sulfamoyl, sulfonylamino, nitro, trifluoromethyl, cyano, azido, heterocyclic, alkylaryl, or aromatic groups.
[0162] The term "alkynyl" includes unsaturated aliphatic groups analogous in length and possible substitution to the alkyls described above, but that contain at least one triple bond.
[0163] For example, the term "alkynyl" includes straight chain alkynyl (e.g., ethynyl, propynyl, butynyl, pentynyl, hexynyl, heptynyl, octynyl, nonynyl, decynyl, etc.), side chain alkynyl, and cycloalkyl or cycloalkenyl substituted alkynyl. The term alkynyl also includes alkynyl containing oxygen, nitrogen, sulphur or phosphorus atoms of one or more carbons replacing hydrocarbon backbone. In certain embodiments, straight or side chain alkynyl has 6 or less carbon atoms (e.g., straight chain of C2-C6, side chain of C3-C6) in its backbone. The term C2-C6 includes alkynyl containing 2-6 carbon atoms.
[0164] In addition, the term alkynyl includes "unsubstituted alkynyl" and "substituted alkynyl", the latter refers to alkynyl having substituents replacing hydrogen on one or more carbons in the hydrocarbon backbone. The substituents may include, for example, alkyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, hydroxycarbonyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, alkoxy, phosphate, -P(O)(O-)2(phosphonato), -PH(O)(O-)(phosphinato), cyano, amino The invention also includes a 3-amino-3-methylamino group, a 4-amino-3-nitro group, a 5-amino-4-nitro group, a 6-amino-3-nitro group, a 7-amino-3-nitro group, a 1-amino-4-nitro group, a 2-amino-3-nitro group, a 2-amino-3-nitro group, a 3-amino-3-nitro group, a 4-amino-3-nitro group, a 5-amino-3-nitro group, a 6 ...5-amino-3-nitro group, a 6-amino-3-nitro group, a 7-amino-3-nitro group, a 7-amino-3-nitro group, a 7-amino-3-nitro group, a 7-amino-3-nitro group, a 7-amino-3-nitro group, a 7-amino-3-nitro group, a 7-amino-3-nitro group, a 7-amino-3-nitro group, a 7-amino-3-nitro group, a 7-amino-3-nitro group, a 7-amino-3-nitro group, a
[0165] The term "C 2-6 The term "alkynyl" includes alkynyl groups containing 2 to 6 carbon atoms.
[0166] The term "alkoxy" includes substituted and unsubstituted alkyl groups covalently linked to an oxygen atom. Examples of alkoxy groups include methoxy, ethoxy, isopropyloxy, propoxy, butoxy and pentoxy. Examples of substituted alkoxy groups include halogenated alkoxy. The alkoxy group may be substituted by alkenyl, alkynyl, halogen, hydroxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, hydroxycarbonyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylthiocarbonyl, phosphate, cyano, amino (including alkylamino, dialkylamino, arylamino, diarylamino and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, thiol, alkylthio, arylthio, hydroxythiocarbonyl, alkylsulfinyl, sulfonic acid, sulfamoyl, sulfonylamino, nitro, trifluoromethyl, cyano, azido, heterocyclic, alkylaryl or aromatic groups.
[0167] The term "cycloalkyl" refers to a monovalent or polyvalent saturated monocyclic, bicyclic or tricyclic ring system containing 3 to 12 carbon atoms, wherein the monocyclic, bicyclic or tricyclic ring does not contain an aromatic ring. The cycloalkyl group may be independently unsubstituted or substituted with one or more substituents described herein.
[0168] The term "hydroxy" includes groups having -OH or -O-.
[0169] The term "halogen" includes fluorine, chlorine, bromine, iodine and the like.
[0170] The term "substituted" as used in the present invention means that any one or more hydrogen atoms on a designated atom are replaced by a substituent selected from a designated group, and the result of the substitution is a stable compound. When the substituent is an oxo group or a keto group (i.e., =O), two hydrogen atoms on the atom are replaced, and the keto substituent does not exist on the aromatic ring.
[0171] The pharmaceutically acceptable salts of the present invention include pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0172] "Pharmaceutically acceptable acid addition salt" refers to a salt formed with an inorganic acid or organic acid that retains the biological effectiveness of the free base without other side effects. Inorganic acid salts include, but are not limited to, hydrochlorides, hydrobromides, sulfates, phosphates, nitrates, and the like; organic acid salts include, but are not limited to, formate, acetate, propionate, 2,2-dichloroacetate, butyrate, caproate, caprylate, decanoate, undecylenate, glycolate, gluconate, lactate, sebacate, adipate, glutarate, malonate, oxalate, maleate, succinate, fumarate, tartrate, citrate, palmitate, stearate, oleate, cinnamate, malate, laurate, glutamate, pyroglutamate, aspartate, benzoate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, alginate, ascorbate, salicylate, 4-aminosalicylate, naphthalene disulfonate, and the like.
[0173] "Pharmaceutically acceptable base addition salt" refers to a salt formed with an inorganic base or an organic base that can maintain the biological effectiveness of the free acid without other side effects. Salts derived from inorganic bases include, but are not limited to, potassium salts, sodium salts, lithium salts, ammonium salts, calcium salts, magnesium salts, iron salts, zinc salts, copper salts, manganese salts, aluminum salts, etc. Preferred inorganic salts are ammonium salts, sodium salts, potassium salts, calcium salts and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, substituted amines, including naturally substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, trimethylamine, isopropylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, triethanolamine, dimethylethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, betaine, choline, ethylenediamine, glucosamine, methylglucosamine, theobromine, purine, piperidine, piperazine, N-ethylpiperidine, polyamine resins, etc. Preferred organic bases include isopropylamine, trimethylamine, diethylamine, ethanolamine, dicyclohexylamine, choline and caffeine.
[0174] When the compound molecule of the present invention contains at least one nitrogen atom that can form a salt, it can be converted into a corresponding salt by reacting with a corresponding organic acid or inorganic acid in an organic solvent such as acetonitrile or tetrahydrofuran. Typical organic acids include oxalic acid, tartaric acid, maleic acid, succinic acid, methanesulfonic acid, benzoic acid, benzenesulfonic acid, toluenesulfonic acid, aminosulfonic acid, citric acid, glutamic acid, pyroglutamic acid, aspartic acid, glucuronic acid, naphthalenesulfonic acid, glutaric acid, acetic acid, trifluoroacetic acid, malic acid, fumaric acid, salicylic acid, 4-aminosalicylic acid, lactic acid, palmitate, stearic acid, lauric acid, cinnamic acid, alginic acid, and ascorbate, and typical inorganic acids include nitric acid, hydrochloric acid, sulfuric acid, and phosphoric acid.
[0175] When there are one or more asymmetric carbon atoms in the compounds of the present invention, they can exist in the following forms: optically pure enantiomers, pure diastereomers, enantiomeric mixtures, diastereomer mixtures, enantiomeric racemic mixtures, racemates or racemate mixtures. All possible isomers, stereoisomers and mixtures thereof of the compounds of formula (II) are also within the scope of the present invention.
[0176] The present invention also provides a pharmaceutical composition comprising at least one compound as described above and optionally one or more pharmaceutically acceptable carriers and / or diluents.
[0177] The pharmaceutical composition provided by the present invention can be prepared in any form, such as granules, powders, tablets, coated tablets, capsules, pills, syrups, drops, solutions, suspensions and emulsions, or sustained-release preparations of active ingredients, wherein examples of capsules include hard or soft gelatin capsules, and granules and powders can be non-effervescent or effervescent forms.
[0178] The pharmaceutical composition of the present invention may further include one or more pharmaceutically or physiologically acceptable carriers, which are suitably formulated for administration. For example, the pharmaceutically or physiologically acceptable carrier may be saline, hot pressed water, Ringer's solution, buffered saline, glucose, maltodextrin, glycerol, ethanol, and mixtures thereof. The pharmaceutical composition of the present invention may also include pharmaceutically or physiologically acceptable additives, such as diluents, lubricants, adhesives, glidants, disintegrants, sweeteners, flavoring agents, wetting agents, dispersants, surfactants, solvents, coating agents, foaming agents, or aromatics.
[0179] Examples of diluents that may be used include, but are not limited to, lactose, sucrose, starch, kaolin, salt, mannitol, and dicalcium phosphate; examples of lubricants include, but are not limited to, talc, starch, magnesium or calcium stearate, lycopodium and stearic acid; examples of binders include, but are not limited to, microcrystalline cellulose, tragacanth gum, glucose solution, acacia gum, gelatin solution, sucrose, and starch paste; examples of glidants include, but are not limited to, colloidal silicon dioxide; examples of disintegrants include, but are not limited to, cross-linked sodium carboxymethylcellulose, sodium starch glycolate, alginic acid, corn starch, maltose, and cellulose acetate. potato starch, bentonite, methylcellulose, agar and carboxymethylcellulose; examples of sweeteners include, but are not limited to, sucrose, lactose, mannitol and artificial sweeteners such as sodium cyclamate and saccharin, and any number of spray-dried flavoring agents; examples of flavoring agents include, but are not limited to, natural flavoring agents extracted from plants, such as fruits, and tastier compounds such as, but not limited to, mint and methyl salicylate; examples of wetting agents include, but are not limited to, propylene glycol monostearate, sorbitan monooleate, diethylene glycol monolaurate and polyoxyethylene lauryl ether.
[0180] The pharmaceutical composition of the present invention can be administered by various routes according to conventional methods, including oral, intravenous, intraarterial, intraperitoneal, intrathoracic, transdermal, nasal, inhalation, rectal, ocular and subcutaneous administration.
[0181] The pharmaceutically acceptable carrier optionally added to the pharmaceutical composition of the present invention is: one or more of water, alcohol, honey, mannitol, sorbitol, dextrin, lactose, caramel, gelatin, calcium sulfate, magnesium stearate, talc, kaolin, glycerol, Tween, agar, calcium carbonate, calcium bicarbonate, surfactants, cyclodextrin and its derivatives, phospholipids, phosphates, starches and its derivatives, silicon derivatives, celluloses and its derivatives, pyrrolidones, polyethylene glycols, acrylic resins, phthalates, acrylic acid copolymers, and trimellitic acid esters.
[0182] Pharmacological experiments have verified that the compounds or pharmaceutical compositions provided by the present invention can treat cancer, myeloproliferative diseases or autoimmune diseases through PD-1. The cancer is nasopharyngeal cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, esophageal cancer, esophageal cancer, gastric cancer, liver cancer, colorectal cancer, rectal cancer, skin cancer, epithelial cell cancer, bladder cancer, nasopharyngeal cancer, blood cancer or bone cancer. The myeloproliferative disease is leukemia, and the autoimmune disease is inflammatory bowel inflammation, autoimmune encephalomyelitis or multiple sclerosis.
[0183] The general dosage range of the compounds provided by the present invention is about 0.001 mg / kg to 1000 mg / kg per day, preferably about 0.01 mg / kg to 100 mg / kg, and more preferably about 0.1 to 20 mg / kg. The dosage range of the pharmaceutical composition is calculated based on the amount of the above-mentioned compound contained therein. DETAILED DESCRIPTION
[0184] Example 1
[0185] N-(2-Chloro-3′-(4-(((2-hydroxyethyl)amino)methyl)-1-methyl-1H-imidazole-2-carboxamido)-2′-methyl-[1,1′-biphenyl]-3-yl)-5-(((2-hydroxyethyl)amino)methyl)picolinamide
[0186]
[0187] Step 1 3-Bromo-2-chloroaniline 1b
[0188] Compound 1a (10 g, 42.372 mol), zinc powder (22 g, 338.98 mmol), ammonium chloride (17.96 g, 338.98 mmol) were dissolved in ethanol (50 mL), THF (50 mL) and H2O (25 mL), heated to 60 ° C and stirred for 6 h, and the reaction was completed. The reaction solution was filtered and dried, and then water and ethyl acetate were added for extraction. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 1b (7 g, 33.98 mmol), with a yield of 80%. MS m / z (ESI): 208 [M+1] + .
[0189] Step 2 6-((3-bromo-2-chlorophenyl)carbamoyl)nicotinate 1c
[0190] Compound 1b (2.06 g, 10 mmol) and 5-(methoxycarbonyl)picolinic acid (2.715 g, 15 mmol) were dissolved in N, N-dimethylformamide (50 mL), HATU (7.6 g, 20 mmol) and DIPEA (5.16 g, 40 mmol) were added, and the reaction was completed after 24 h at room temperature. The reaction solution was washed with water, extracted with dichloromethane three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 1c (2 g, 5.42 mmol), with a yield of 54%. MS m / z (ESI): 371 [M+H] + .
[0191] Step 3 6-((2-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)carbamoyl)nicotinate 1d
[0192] Compound 1c (1.8 g, 4.878 mmol) and biboronic acid pinacol ester (2.478 g, 9.756 mmol) were dissolved in dioxane (50 mL), and [1,1′-bis(diphenylphosphino)ferrocene] palladium dichloride (0.356 g, 0.4878 mmol) and potassium acetate (1.434 g, 14.634 mmol) were added. The mixture was heated to 100°C and stirred for 4 h under the protection of argon gas, and the reaction was completed. Water and ethyl acetate were added to the reaction solution for extraction, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 1d (1.6 g, 3.846 mmol) with a yield of 78.8%. MS m / z (ESI) 417 [M+1] + .
[0193] Step 4: 1-methyl-1H-imidazole-4-carboxylic acid methyl ester 1f
[0194] Compound 1e (5 g, 39.68 mmol) was dissolved in methanol (100 mL), and then thionyl chloride (9.44 g, 79.36 mmol) was slowly added dropwise. After heating and reflux for 6 h, the reaction was completed. The reaction solution was spin-dried and added with a saturated sodium bicarbonate solution, extracted three times with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 1f (3.6 g, 0.4 mmol) with a yield of 63.7%. MS m / z (ESI): 141.2 [M+H] + .
[0195] Step 5: 4-(Methoxycarbonyl)-1-methyl-1H-imidazole-2-carboxylic acid 1g
[0196] Compound 1f (1 g, 7.14 mmol) was dissolved in tetrahydrofuran (40 mL), and LDA (14.3 mL, 14.3 mmol) was slowly added dropwise in a dry ice acetone bath under argon protection. After stirring for 1 h, a CO2 balloon was replaced. After reacting at -78 ° C for 1 h, the temperature was slowly raised to room temperature, stirred overnight, quenched with water, and adjusted to pH = 4-5 with dilute hydrochloric acid. The mixture was extracted three times with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the title compound 1g (560 mg, 3.04 mmol), with a yield of 42.6%. MS m / z (ESI): 185.1 [M+1] + .
[0197] Step 6: 2-((3-bromo-2-methylphenyl)carbamoyl)-1-methyl-1H-imidazole-4-carboxylic acid methyl ester 1h
[0198] Compound 1g (560 mg, 3.043 mmol) and 3-bromo-2-methylaniline (849 mg, 4.565 mmol) were dissolved in N, N-dimethylformamide (20 mL), HATU (2.312 g, 6.086 mmol) and DIPEA (1.57 g, 12.172 mmol) were added, and the reaction was completed after 24 h at room temperature. The reaction solution was washed with water, extracted with dichloromethane three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 1h (500 mg, 1.42 mmol), with a yield of 46%. MS m / z (ESI): 352.1 [M+H] + .
[0199] Step 7: Methyl 6-((2-chloro-3′-(4-(methoxycarbonyl)-1-methyl-1H-imidazole-2-carboxamido)-2′-methyl-[1,1′-biphenyl]-3-yl)carbamate)nicotinate 1i
[0200] Compound 1h (500 mg, 1.42 mmol) and 1d (886 mg, 2.13 mmol) were dissolved in 1,4-dioxane (50 mL) and water (15 mL), and [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride (104 mg, 0.142 mmol) and potassium phosphate (903 mg, 4.26 mmol) were added. The mixture was heated to 100°C and stirred for 5 h under the protection of argon gas, and the reaction was completed. Water and ethyl acetate were added to the reaction solution for extraction, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 1i (300 mg, 0.534 mmol) with a yield of 37%. MS m / z (ESI): 562.3 [M+H] + .
[0201] Step 8: N-(2-chloro-3′-(4-(hydroxymethyl)-1-methyl-1H-imidazole-2-carboxamide)-2′-methyl-[1,1′-biphenyl]-3-yl)-5-(hydroxymethyl)picolinic acid amide 1j
[0202] Compound 1i (200 mg, 0.3558 mmol) was dissolved in ethanol (20 mL), and sodium borohydride (134.5 mg, 3.558 mmol) was added under the protection of argon in an ice bath, and the mixture was slowly heated to room temperature and stirred overnight to complete the reaction. The reaction solution was quenched with dilute hydrochloric acid, and then saturated sodium bicarbonate was added. The mixture was extracted three times with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 1j (100 mg, 0.198 mmol) with a yield of 55%. MS m / z (ESI): 506.3 [M+H] +
[0203] Step 9: N-(2-chloro-3′-(4-formyl-1-methyl-1H-imidazole-2-carboxamide)-2′-methyl-[1,1′-biphenyl]-3-yl)-5-formylpyridinol 1k
[0204] Compound 1j (100 mg, 0.198 mmol) was dissolved in dichloromethane (20 mL), and Dess-Martin reagent (252 mg, 0.594 mmol) was added. After reacting at room temperature for 2 h, the reaction was completed. The reaction solution was quenched with sodium sulfite, extracted three times with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by plate chromatography to obtain the title compound 1k (65 mg, 0.1297 mmol) with a yield of 65%. MS m / z (ESI): 502.3 [M+H] + .
[0205] Step 10: 5-((((2-((tert-butyldimethylsilyl)oxy)ethyl)amino)methyl)-N-(3′-(4-(((((2-((tert-butyldimethylsilylmethoxy)ethyl)amino]methyl)-1-methyl-1H-imidazole-5-carboxamido)-2-chloro-2′-methyl-[1,1′-biphenyl]-3-yl)picolinamide 11
[0206] Compound 1k (65 mg, 0.1297 mmol) was dissolved in dichloromethane (20 mL), acetic acid (16 mg, 0.2594 mmol) and 2-((tert-butyldimethylsilyl)oxy)ethyl-1-amine (89 mg, 0.5189 mmol) were added, and the reaction solution was stirred at room temperature for 30 minutes, and then sodium acetate borohydride (165 mg, 0.7782 mmol) was added. After stirring at room temperature for 13 hours, the reaction was completed. The reaction solution was quenched with water, extracted with dichloromethane three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by plate chromatography to obtain the title compound 1l (75 mg, 0.091 mmol) with a yield of 70%. MS m / z (ESI): 820.7 [M+1] + .
[0207] Step 11: N-(2-chloro-3′-(4-(((2-hydroxyethyl)amino)methyl)-1-methyl-1H-imidazole-2-carboxamido)-2′-methyl-[1,1′-biphenyl]-3-yl)-5-(((2-hydroxyethyl)amino)methyl)picolinamide 1
[0208] Compound 11 (75 mg, 0.091 mmol) was dissolved in tetrahydrofuran (10 mL), TBAF / THF (0.73 mL, 0.73 mmol) was added, and the reaction solution was stirred at room temperature for 3 h before the reaction was completed. After concentration, the title compound 1 (23 mg, 0.03885 mmol) was obtained by Prep-HPLC purification with a yield of 42%. MS m / z (ESI): 592.4 [M+1] +
[0209] 1 H NMR (400MHz, DMSO-d6) δ10.70 (s, 1H), 8.74 (s, 1H), 8.42 (d, J=8.3Hz, 1H), 8.21 (d, J=8.1H z, 1H), 8.12 (d, J=7.8Hz, 2H), 7.76 (s, 1H), 7.49 (q, J=7.8Hz, 2H), 7.28 (t, J=7.8Hz, 1H), 7. 10 (d, J=7.5Hz, 1H), 7.01 (d, J=7.5Hz, 1H), 4.73 (s, 2H), 4.08 (s, 2H), 3.97 (s, 2H), 3.81 (s , 3H), 3.55 (t, J=5.6Hz, 2H), 3.47 (s, 2H), 2.79 (t, J=5.2Hz, 2H), 2.68 (s, 2H), 1.97 (s, 3H).
[0210] Example 2
[0211] N-(2′-chloro-3′-(5-((((2-hydroxyethyl)amino)methyl)picolinamido)-2-methyl-[1,1′-biphenyl]-3-yl)-4-(((2-hydroxyethyl)amino)methyl)thiazole-2-carboxamide
[0212]
[0213] The title product 2 was prepared by a synthetic method similar to that of Example 1.
[0214] MS m / z(ESI):595.4[M+1] +
[0215] 1H NMR (400MHz, DMSO-d6) δ10.70 (s, 1H), 10.29 (s, 1H), 8.66 (d, J=2.0Hz, 1H), 8.46 (dd, J=8.2, 1. 6Hz, 1H), 8.15 (d, J=8.0Hz, 1H), 8.02 (dd, J=8.0, 2.0Hz, 1H), 7.79 (s, 1H), 7.55-7.44 (m, 2H), 7. 30 (t, J=7.8Hz, 1H), 7.08 (ddd, J=6.5, 5.0, 1.4Hz, 2H), 4.47 (q, J=5.8Hz, 2H), 3.88 (s, 2H), 3.82 (s, 2H), 3.44 (dt, J=8.8, 5.4Hz, 4H), 2.62 (t, J=5.7Hz, 2H), 2.54 (t, J=5.8Hz, 2H), 1.97 (s, 3H).
[0216] Example 3
[0217] (S)-N-(5-(3-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-4-methylpyridin-3-yl)-5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide
[0218]
[0219] Step 1 Tert-butyl 1-methyl-2-((2-methyl-3-(4-methyl-5-nitropyridin-3-yl)phenyl)carbamoyl)-1,4,6,7-tetrahydro-5H-imidazole[4,5-c]pyridine-5-carboxylate 3c
[0220] Compounds 3a (1.02 g, 4.21 mmol) and 3b (1.18 g, 4.21 mmol) were dissolved in DMSO (20 mL), HATU (1.75 g, 4.63 mmol) and TEA (1.27 g, 12.6 mmol) were added, nitrogen was replaced three times, and stirred at room temperature for 20 h. Water was added to the reaction solution, extracted three times with EtOAc, washed several times with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 3c (1.03 g, yield 48%). MS m / z (ESI): 507.4 [M+1] + .
[0221] Step 2 1-Methyl-N-(2-methyl-3-(4-methyl-5-nitropyridin-3-yl)phenyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide hydrochloride 3d
[0222] Compound 3c (1.00 g, 1.97 mmol) was dissolved in EtOAc (10 mL), HCl / EtOAc (2N, 10 mL) was added, and the reaction solution was stirred at room temperature for 2 h. The reaction solution was evaporated to dryness to obtain the crude product of the title compound 3d (730 mg), which was used directly in the next step without purification. MS m / z (ESI): 407.3 [M+1] + .
[0223] Step 3 1,5-dimethyl-N-(2-methyl-3-(4-methyl-5-nitropyridin-3-yl)phenyl)-4,5,6,7-tetrahydro-1H-imidazole [4,5-c] pyridine-2-carboxamide 3e
[0224] Compound 3d (730 mg, 1.00 mmol) was dissolved in dichloromethane (40 mL) and methanol (4.0 mL), polyaldehyde (1.80 g, 20.0 mmol) was added, and then sodium acetate borohydride (1.05 g, 5.00 mmol) was added. After stirring at room temperature for 20 minutes, the reaction was completed. The reaction solution was quenched with a saturated aqueous NaHCO3 solution, extracted three times with dichloromethane, dried and filtered with anhydrous sodium sulfate, concentrated and purified by column chromatography to obtain the title compound 3e (384 mg, yield 82%). MS m / z (ESI): 421.3 [M+1] + .
[0225] Step 4: N-(3-(5-amino-4-methylpyridin-3-yl)-2-methylphenyl)-1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-2-carboxamide 3f
[0226] Compound 3e (350 mg, 0.83 mmol) was dissolved in EtOH (10 mL), and Pd / C (50 mg) was added. The reaction solution was stirred at 52 °C for 4 h under hydrogen gas, filtered, and the filtrate was concentrated to obtain 3f (211 mg, yield 64%) as a white solid, which was used directly in the next step without purification.
[0227] MS m / z(ESI):391.3[M+1] + .
[0228] Step 5: 1,5-dimethyl-N-(2-methyl-3-(4-methyl-5-(1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide)pyridin-3-yl)phenyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide hydrochloride for 3h
[0229] Compound 3f (100 mg, 0.25 mmol) and 3g (150 mg, 0.50 mmol) were dissolved in toluene (10 mL), cooled to -78 °C, and LiHDMS (0.5 mL, 0.50 mmol) was slowly added. The reaction mixture was reacted overnight at room temperature. Water was added to the reaction solution, extracted with EtOAC, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the BOC-protected title compound (50 mg, yield 30%) as a light-colored oil. HCl / EtOAc (5.0 mL) was added, stirred at room temperature for 2 h, and concentrated to obtain the crude product of the title compound 3h, which was directly used in the next step.
[0230] MS m / z(ESI):554[M+1] + .
[0231] Step 6 (S)-5-(2-((tert-butyldimethylsilyl)oxy)propyl)-N-(5-(3-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-4-methylpyridin-3-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 3j
[0232] Compound 3h (50 mg, 0.07 mmol) and compound 3i (39 mg, 0.21 mmol) were dissolved in dichloromethane (20 mL) and methanol (2 mL), and sodium borohydride acetate (74 mg, 0.35 mmol) was added. After stirring overnight at room temperature, the reaction was completed. The reaction solution was quenched with NaHCO3 aqueous solution, extracted three times with dichloromethane, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 3j (60 mg, crude product), which was directly used in the next step.
[0233] MS m / z(ESI):726.7[M+1] + .
[0234] Step 8 (S)-N-(5-(3-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-4-methylpyridin-3-yl)-5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 3
[0235] Compound 3j (60 mg, 0.07 mmol) was dissolved in EtOAc (5 mL), HCl / EtOAc (2N, 5 mL) was added, and the mixture was stirred at room temperature for 5 h. The pH value was adjusted to neutral with 15% aqueous sodium bicarbonate solution, and the mixture was extracted with EA. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to give the title compound 3 (8.0 mg, yield 18%).
[0236] MS m / z(ESI):612.5[M+1] +
[0237] 1 H NMR (400MHz, DMSO-d6) δ10.00 (s, 1H), 9.77 (s, 1H), 8.61 (s, 1H), 8.11 (s, 1H), 7.65 (dd, J=8. 1, 1.3Hz, 1H), 7.28 (t, J=7.8Hz, 1H), 6.98 (dd, J=7.6, 1.3Hz, 1H), 5.29 (s, 1H), 4.34 (d, J=4.1 Hz, 1H), 3.83 (d, J=2.7Hz, 5H), 3.47 (d, J=3.5Hz, 3H), 2.79 (t, J=5.8Hz, 2H), 2.64 (q, J=4.2Hz , 6H), 2.40-2.33 (m, 3H), 1.94 (t, J=6.5Hz, 7H), 1.43 (d, J=7.7Hz, 1H), 1.04 (d, J=6.1Hz, 3H).
[0238] Example 4
[0239] (R)-1-(((2-(2,2′-dimethyl-3′-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido))-[1,1′-biphenyl]-3-yl) oxazolyl[5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid
[0240]
[0241] Step-5-(3-bromo-2-methylbenzamido)-6-chloronicotinic acid methyl ester 4c
[0242] Compound 4a (6.45 g, 30 mol) and compound 4b (5.58 g, 30 mmol) were dissolved in pyridine (30 mL), phosphorus oxychloride (9.18 g, 60 mol) was slowly added dropwise under ice bath, stirred at room temperature for 3 hours, and the reaction was completed. Ice water was added and extracted with ethyl acetate, the organic phase was washed with saturated copper sulfate solution and saturated salt water, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography to obtain the title compound 4c (4 g, 10.44 mmol), with a yield of 35%.
[0243] MS m / z(ESI):385.1[M+1] + .
[0244] Step 2 2-(3-bromo-2-methylphenyl) Methyl oxazolo[5,4-b]pyridine-6-carboxylate 4d
[0245] Compound 4c (3 g, 7.832 mmol) and N, N'-dimethylethylenediamine (69 mg, 0.7832 mmol) were dissolved in toluene (50 mL), and CuI (149 mg, 0.7832 mmol) and potassium carbonate (2.161 g, 15.664 mmol) were added. The mixture was heated to 120 ° C and stirred for 24 h under the protection of argon gas, and the reaction was completed. The reaction solution was added with water and extracted with ethyl acetate three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 4d (1.5 g, 4.322 mmol) with a yield of 55%.
[0246] MS m / z(ESI):347[M+H] + .
[0247] Step 3 Methyl (2-(3-bromo-2-methylphenyl) Oxazo[5,4-b]pyridin-6-yl)methanol 4e
[0248] Compound 4d (3 g, 8.645 mmol) was dissolved in dichloromethane (60 mL), cooled to -78 ° C under argon protection, and then DIBAL-H (11.5 mL, 17.29 mmol) was slowly added. After the addition was complete, it was stirred at this temperature for 1 hour, then warmed to room temperature, quenched with water, and then saturated potassium sodium tartrate was added, followed by extraction with ethyl acetate. The organic phase was washed with saturated sodium carbonate and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give the title compound 4e (2.2 g, 6.89 mmol) in a yield of 79%.
[0249] MS m / z(ESI)319[M+1] + .
[0250] Step 4: 2-(3-bromo-2-methylphenyl) Azo[5,4-b]pyridine-6-carboxaldehyde 4f
[0251] Compound 4e (1.5 g, 4.702 mmol) was dissolved in dichloromethane (50 mL), and then Dess-Martin periodinane (3.987 g, 9.404 mmol) was added, and the reaction was carried out at room temperature for two hours. After adding sodium thiosulfate solution and stirring for 1 hour, the mixture was extracted with ethyl acetate three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 4f (1.2 g, 3.785 mmol) with a yield of 80%.
[0252] MS m / z(ESI):317.1[M+H] + .
[0253] Step 5: Methyl (R)-1-((2-(3-bromo-2-methylphenyl) Methyl oxazolo[5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylate 4h
[0254] Compound 4f (1.2 g, 3.785 mmol) and (R)-pyrrolidine-3-carboxylic acid methyl ester hydrochloride 4g (1.249 g, 7.57 mmol) were dissolved in dichloromethane (60 mL), and sodium triethoxyborohydride (2.407 mg, 11.356 mmol) was added after stirring for 1 hour. After stirring overnight at room temperature, the reaction was completed. Water and ethyl acetate were added to the reaction solution for extraction, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 4f (0.7 g, 1.627 mmol) with a yield of 43%.
[0255] MS m / z(ESI):430.2[M+1] + .
[0256] Step 6 (R)-1-(((2-(2,2′-dimethyl-3′-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido))-[1,1′-biphenyl]-3-yl) Compound 4h (100 mg, 0.2325 mmol) and 4i (144 mg, 0.3488 mmol) of oxazolyl [5, 4-b] pyridine-6-yl) methyl) pyrrolidine-3-carboxylic acid 4 were dissolved in tert-butyl alcohol / water (v / v = 2 / 1) (15 mL), 1,1′-bis (di-cyclohexylphosphino) ferrocene palladium dichloride (18 mg, 0.02325 mmol) and cesium carbonate (227 mg, 0.6975 mmol) were added, and the reaction was completed after 4 hours at ℃ under argon protection. After filtration, the mixture was spin-dried and washed with methanol, the organic phase was filtered, concentrated, and purified by preparative Prep-HPLC to obtain the title compound 4 (30 mg, 0.04823 mmol) with a yield of 20%.
[0257] MS m / z(ESI):623.5[M+1] +
[0258] 1 H NMR (400MHz, Methanol-d4) δ8.39 (d, J=2.0Hz, 1H), 8.25 (d, J=2.0Hz, 1H), 8.17 (dd, J=7.9, 1.5Hz, 1H), 7.71-7.65 (m, 1H), 7.52-7.45 (m, 1H), 7.40-7. 31 (m, 2H), 7.11-7.06 (m, 1H), 4.12-3.95 (m, 2H), 3.80 (d, J=1.6Hz, 2H), 3.1 4-2.75 (m, 9H), 2.50 (d, J=13.8Hz, 6H), 2.14 (q, J=7.2Hz, 2H), 2.04 (s, 3H).
[0259] Example 5
[0260] N-(5-(3-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-4-methylpyridin-3-yl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide
[0261]
[0262] The title product 5 was prepared by a synthetic method similar to that of Example 3.
[0263] MS m / z(ESI):571.4[M+1] +
[0264] 1H NMR (400MHz, DMSO-d6) δ10.54(s, 2H), 9.78(s, 1H), 8.53(s, 1H), 8.16(s, 1H) , 7.65 (dd, J=8.0, 1.2Hz, 1H), 7.29 (t, J=7.8Hz, 1H), 6.99 (dd, J=7.6, 1.4Hz, 1H), 3.83 (s, 3H), 3.68 (t, J=1.6Hz, 2H), 2.89 (t, J=5.8Hz, 2H), 2.75 (t, J=5. 8Hz, 2H), 2.65 (t, J=3.6Hz, 6H), 2.37 (d, J=7.9Hz, 5H), 1.93 (d, J=9.1Hz, 6H).
[0265] Example 6
[0266] N-(5-(3-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-4-methylpyridin-3-yl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide
[0267]
[0268] The title product 6 was prepared by a synthetic method similar to that of Example 3.
[0269] MS m / z(ESI):615.5[M+1] +
[0270] 1 H NMR (400MHz, DMSO-d6) δ10.57 (s, 1H), 9.78 (s, 1H), 8.56 (s, 1H), 8.19 (s, 1H), 7.73-7.67 (m, 1H), 7.32 (t, J=7.8Hz, 1H), 7.01 (dd, J=7.6, 1.3Hz, 1H), 4.37 (d, J=4.0Hz, 1H), 3.86 (s , 4H), 3.71 (d, J=1.8Hz, 2H), 3.49 (s, 2H), 2.91 (d, J=6.0Hz, 2H), 2.85-2.76 (m, 4H), 2.65 (s, 2H), 2.46 (d, J=6.9Hz, 1H), 2.41 (s, 4H), 1.96 (d, J=8.6Hz, 6H), 1.06 (d, J=6.1Hz, 3H).
[0271] Example 7
[0272] (R)-1-((2-(3′-((3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) oxazolo[5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid
[0273]
[0274]
[0275] Step 1 Methyl 5-(3-bromo-2-methylbenzamido)-6-chloronicotinate 7c
[0276] Compound 7a (6.45 g, 30 mol) and compound 7b (5.58 g, 30 mmol) were dissolved in pyridine (30 mL), phosphorus oxychloride (9.18 g, 60 mol) was slowly added dropwise under ice bath, stirred at room temperature for 3 hours, and the reaction was completed. After adding ice water, it was extracted with ethyl acetate, and the organic phase was washed with saturated copper sulfate solution and saturated salt water, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography to obtain the title compound 7c (4 g, 10.44 mmol), with a yield of 35%.
[0277] MS m / z(ESI):385.1[M+1] + .
[0278] Step 2 2-(3-bromo-2-methylphenyl) Methyl oxazolo[5,4-b]pyridine-6-carboxylate 7d
[0279] Compound 7c (3 g, 7.832 mmol) and N, N'-dimethylethylenediamine (69 mg, 0.7832 mmol) were dissolved in toluene (50 mL), and CuI (149 mg, 0.7832 mmol) and potassium carbonate (2.161 g, 15.664 mmol) were added. The mixture was heated to 120°C and stirred for 24 h under the protection of argon gas, and the reaction was completed. The reaction solution was added with water and extracted with ethyl acetate three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 7d (1.5 g, 4.322 mmol) with a yield of 55%.
[0280] MS m / z(ESI):347[M+H] + .
[0281] Step 3 (2-(3-bromo-2-methylphenyl) Oxazo[5,4-b]pyridin-6-yl)methanol 7e
[0282] Compound 7d (3 g, 8.645 mmol) was dissolved in dichloromethane (60 mL), cooled to -78 ° C under argon protection, and then DIBAL-H (11.5 mL, 17.29 mmol) was slowly added. After the addition was complete, it was stirred at this temperature for 1 hour, then warmed to room temperature, quenched with water, and then saturated potassium sodium tartrate was added, followed by extraction with ethyl acetate. The organic phase was washed with saturated sodium carbonate and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give the title compound 7e (2.2 g, 6.89 mmol) in a yield of 79%.
[0283] MS m / z(ESI)319[M+1] + .
[0284] Step 4: 2-(3-bromo-2-methylphenyl) Azo[5,4-b]pyridine-6-carboxaldehyde 7f
[0285] Compound 7e (1.5 g, 4.702 mmol) was dissolved in dichloromethane (50 mL), and then Dess-Martin periodinane (3.987 g, 9.404 mmol) was added, and the reaction was carried out at room temperature for two hours. After adding sodium thiosulfate solution and stirring for 1 hour, the mixture was extracted with ethyl acetate three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 7f (1.2 g, 3.785 mmol) with a yield of 80%.
[0286] MS m / z(ESI):317.1[M+H] + .
[0287] Step 5: Methyl (R)-1-(((2-(3-bromo-2-methylphenyl) Methyl oxazolo[5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylate 7h
[0288] Compound 7f (1.2 g, 3.785 mmol) and (R)-pyrrolidine-3-carboxylic acid methyl ester hydrochloride 7g (1.249 g, 7.57 mmol) were dissolved in dichloromethane (60 mL), stirred for 1 hour, sodium triethoxyborohydride (2.407 mg, 11.356 mmol) was added, and stirred overnight at room temperature to complete the reaction. Water and ethyl acetate were added to the reaction solution for extraction, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 7h (0.7 g, 1.627 mmol) with a yield of 43%.
[0289] MS m / z(ESI):430.2[M+1] + .
[0290] Step 6 (E)-5-bromo-3-(2-(dimethylamino)vinyl)-2-cyanopyridine 7k
[0291] Compound 5-bromo-3-methyl-2-cyanopyridine 7j (30 g, 152 mmol) and compound N,N-dimethylformamide dimethyl acetal (36 g, 304 mmol) were dissolved in N,N-dimethylformamide (100 mL), heated to 140°C and reacted for 20 h. The solvent was then dried, ethyl acetate was added, and the sample was purified by column chromatography to obtain the title compound 7k (18 g, 91.3 mmol) with a yield of 60%.
[0292] Step 7 3-bromo-1,7-naphthyridin-8-(7H)-one 71
[0293] Compound (E)-5-bromo-3-(2-(dimethylamino)vinyl)-2-cyanopyridine 7k (18 g, 91.3 mmol) was dissolved in ethanol (80 mL), and hydrobromic acid (23 g, 285 mmol) was added and heated to 90°C for 6 h. The yellow solid was filtered out and the hydrobromic acid was washed off with sodium bicarbonate solution to obtain the title compound 7l (6.8 g, 30.2 mmol) with a yield of 33.1%.
[0294] MS m / z(ESI):227[M+1] + .
[0295] Step 8 3-Bromo-8-chloro-1,7-naphthyridine 7m
[0296] Compound 3-bromo-1,7-naphthyridin-8-(7H)-one 7l (6.8 g, 30.2 mmol) was dissolved in phosphorus oxychloride (50 mL) and heated at 110°C for 3 h. The reaction solution was dropped into ice water and extracted with ethyl acetate three times. The organic phase was dried over anhydrous sodium sulfate and purified by column chromatography to obtain the title compound 7m (4.1 g, 16.8 mmol) with a yield of 55.6%.
[0297] MS m / z(ESI):244.9[M+1] + .
[0298] Step 9 8-Chloro-3-vinyl-1,7-naphthyridine 7o
[0299] Compound 7m (2 g, 8.23 mmol) and 7n (1.394 g, 9.053 mmol) were dissolved in 1,4-dioxane / water (v / v=4 / 1) (50 mL), and [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride (601 mg, 0.823 mmol) and sodium carbonate (1.744 g, 16.46 mmol) were added. After reacting at 110° C. for 4 hours under argon protection, the reaction was completed. The reaction solution was added with water and extracted with ethyl acetate three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 7o (800 mg, 4.21 mmol) with a yield of 51%.
[0300] MS m / z(ESI):191[M+1] + .
[0301] Step 10: 8-Chloro-1,7-naphthyridine-3-carboxaldehyde 7p
[0302] Under ice bath, potassium osmate (31 mg, 0.0842 mmol) was added to compound 7o (800 mg, 4.21 mmol) in 1,4-dioxane / water (v / v=4 / 1) (50 mL), stirred for 1 hour, and sodium periodate (1.8 g, 8.42 mmol) was added. After warming to room temperature, the mixture was stirred overnight to complete the reaction. The reaction solution was extracted with ethyl acetate three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 7p (600 mg, 3.125 mmol) in a yield of 74%.
[0303] MS m / z(ESI):193[M+1] + .
[0304] Step 11 (R)-1-((8-chloro-1,7-naphthyridin-3-yl)methyl)pyrrolidin-3-ol 7r
[0305] Compound 7p (800 mg, 4.1666 mmol) and (R)-pyrrolidin-3-ol 7q (1.0879 g, 12.513 mmol) were dissolved in dichloromethane (40 mL), acetic acid (250 mg, 0.41666 mmol) was added, and sodium triethoxyborohydride (2.65 mg, 12.513 mmol) was added after stirring for 1 hour. After stirring overnight at room temperature, the reaction was completed. Saturated sodium bicarbonate and ethyl acetate were added to the reaction solution for extraction, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 7r (0.72 g, 2.737 mmol) with a yield of 65%.
[0306] MS m / z(ESI):264.1[M+1] + .
[0307] Step 12 (R)-1-((8-((2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-di (boryl)phenyl)amino)-1,7-naphthyridin-3-yl)methyl)pyrrolidin-3-ol 7t
[0308] Compounds 7r (700 mg, 2.661 mmol) and 7s (682 mg, 2.927 mmol) were dissolved in isopropanol (40 mL), and HCl / dioxane (1.33 mL, 5.322 mmol) was added. The mixture was heated to 95°C and stirred for 4 hours. The mixture was spin-dried and extracted with saturated sodium bicarbonate and ethyl acetate. The organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to give the title compound 7t (0.65 g, 1.41 mmol) in a yield of 53%.
[0309] MS m / z(ESI):461.3[M+1] + .
[0310] Step 13 (R)-1-((2-(3′-((3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) oxazolo[5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid 7
[0311] Compound 7h (120 mg, 0.279 mmol) and 7t (192 mg, 0.4186 mol) were dissolved in tert-butyl alcohol / water (v / v=2 / 1) (15 mL), 1,1′-bis(di-cyclohexylphosphino)ferrocenepalladium dichloride (21 mg, 0.02791 mmol) and cesium carbonate (240 mg, 0.837 mmol) were added, and the reaction was completed at 100° C. under argon protection for 4 hours. After filtration, the mixture was spin-dried and washed with methanol, the organic phase was filtered, concentrated, and purified by preparative Prep-HPLC to obtain the title compound 7 (34 mg, 0.0508 mmol) with a yield of 18%.
[0312] MS m / z(ESI):670.5[M+1] + .
[0313] 1H NMR (400MHz, DMSO-d6) δ9.30 (s, 1H), 8.83 (d, J = 2.1Hz, 1H), 8.44 (dd, J = 8.2, 1.3Hz, 1H), 8.31 (d, J = 1.9Hz, 1H), 8.14 (ddd, J = 14.7, 7.3, 1.7H z, 3H), 8.03 (d, J=5.8Hz, 1H), 7.51 (t, J=7.7Hz, 1H), 7.40 (dd, J=7.6, 1.5Hz, 1H), 7.32 (t, J=7.8Hz, 1H), 7.15 (d, J=5.8Hz, 1H), 6.89 (dd, J=7 .5, 1.3Hz, 1H), 4.19 (dt, J=6.8, 3.4Hz, 1H), 3.75 (dq, J=21.2, 13.4Hz, 5H), 3.00-2.85 (m, 2H), 2.70 (ddd, J=9.9, 7.2, 3.1Hz, 2H), 2.62 (q, J= 7.4, 6.7Hz, 2H), 2.58-2.49 (m, 2H), 2.44 (s, 3H), 2.35 (dd, J=9.7, 3.7Hz, 1H), 2.06 (s, 3H), 1.96 (dq, J=21.1, 6.9Hz, 3H), 1.61-1.51 (m, 1H).
[0314] Example 8
[0315] (R)-1-((7-chloro-2-(2-methyl-3-(4-methyl-5-(5-methyl-4,5,6,7-tetrahydrothiazol[5,4-c]pyridine-2-carboxamido)pyridin-3-yl)phenyl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0316]
[0317] The first step (2-(3-bromo-2-methylphenyl)-7-chlorobenzo[d] oxazol-5-yl)methanol
[0318] Compound 8a (1.90 g, 5.00 mmol) was dissolved in THF (20 mL), replaced with nitrogen three times at room temperature, and DIBAL-H (10 mL, 10 mmol) was added at -78 ° C. The system was stirred at room temperature for 20 h. Water was added to the reaction solution, extracted three times with DCM (30 mL × 3), washed several times with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the target compound 8b (crude product, white solid), which was directly used in the next step without further purification.
[0319] MS m / z(ESI):354[M+1] + .
[0320] Step 2: 2-(3-bromo-2-methylphenyl)-7-chlorobenzo[d] Azole-5-carboxaldehyde
[0321] The crude compound 8b from the previous step was dissolved in DCM / 1,4-dioxane (10 / 5 mL), and DMP (10.6 g, 25 mmol) was added at room temperature. The reaction solution was stirred at room temperature for 20 h. The reaction solution was adjusted to neutral with saturated NaHCO3, extracted three times with DCM (30 mL×3), washed several times with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (SiO2, PE / EA=5:1) to obtain the title compound 8c (780 mg). The crude product was used directly in the next step without further purification.
[0322] MS m / z(ESI):352[M+1] + .
[0323] Step 3 (R)-1-(((2-(3-bromo-2-methylphenyl)-7)-chlorobenzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid methyl ester
[0324] Sodium acetate borohydride (1.40 g, 6.66 mmol) was added to a mixture of compound 8c (780 mg, 2.22 mmol) and compound 8d (431 mg, 3.34 mmol) in DCM (10 mL), and the mixture was stirred at room temperature for 20 h. The reaction solution was adjusted to neutrality with saturated NaHCO3 aqueous solution, extracted three times with dichloromethane, dried and filtered with anhydrous sodium sulfate, concentrated, and purified by column chromatography (SiO2, PE / EA=20:1 to 2:1) to obtain the target compound 8e (463 mg, white solid), which was used directly in the next step without further purification.
[0325] MS m / z(ESI):463[M+1] + .
[0326] Step 4: Methyl (R)-1-(((7-chloro-2-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylate
[0327] Take a single-mouth bottle, add compound 8e (463 mg, 1.00 mmol), BP (506 mg, 2.00 mmol), KOAc (300 mg, 3.00 mmol), Pd (dppf) Cl2 (463 mg, 1.00 mmol) and 1,4-dioxane (20 mL) in sequence, replace with N2 three times at room temperature, and stir the reaction at 110 ° C for 5 h. After the reaction system is concentrated, it is purified by column chromatography (SiO2, PE / EA = 5: 1 to 1: 1) to obtain the target compound 8f (312 mg, yield 77%) as a white solid.
[0328] MS m / z(ESI):511[M+1] + .
[0329] Step 5: Methyl (R)-1-(((7-chloro-2-(2-methyl-3-(4-methyl-5-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)pyridin-3-yl)phenyl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylate
[0330] Take a single-mouth bottle, add compound 8g (346 mg, 0.94 mmol) and compound 8f (401 mg, 0.78 mmol), 1,4-dioxane / H2O (4:1, 25 mL), K2CO3 (322 mg, 2.34 mmol) and Pd(PPh3)4 (180 mg, 0.15 mmol) in sequence, replace with N2 three times at room temperature, and then react at 110°C for 3 h. Add water to the reaction solution, extract with EtOAC (50 mL×3), combine the organic phases, dry over anhydrous sodium sulfate, filter, concentrate and purify by column chromatography (SiO2, DCM / MeOH=20:1) to obtain the target compound 8h (190 mg, impure), brown oil. Directly apply to the next step without further purification. MS m / z(ESI): 671[M+1] + .
[0331] Step 6 (R)-1-((7-chloro-2-(2-methyl-3-(4-methyl-5-(5-methyl-4,5,6,7-tetrahydrothiazolidine[5,4-c]pyridine-2-carboxamido)pyridin-3-yl)phenyl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0332] Compound 8h (190 mg, 0.28 mmol) was dissolved in methanol (5.0 mL), and LiOH (1 M, 1.4 mL) aqueous solution was added. The reaction was stirred at 50 ° C for 3 h, and the reaction was completed. The pH was adjusted to weak acidity with acetic acid. After concentration, column chromatography (C18, MeCN / H2O) was purified to give the title compound 8 (10.0 mg, white solid).
[0333] MS m / z(ESI):657[M+1] +
[0334] 1 H NMR (400MHz, DMSO-d6) δ10.76 (s, 1H), 8.59 (s, 1H), 8.28 (s, 1H), 8.18 (d, J = 7.8Hz, 1H), 8.00 (s, 1H), 7.76 (s, 1H), 7.57 (d, J = 7.7Hz, 1H), 7.46 ( d, J=7.4Hz, 1H), 4.51 (s, 2H), 3.65 (s, 8H), 3.19 (d, J=6.2Hz, 3H), 2.98 ( s, 3H), 2.40 (s, 2H), 2.30-2.10 (m, 2H), 1.98 (s, 3H), 1.74-1.64 (m, 1H).
[0335] Example 9
[0336] (R)-1-(((7-chloro-2-(4-methyl-5-(2-methyl-3-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)phenyl)pyridin-3-yl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0337]
[0338] Step 1 5-Bromo-4-methylnicotinamide 9b
[0339] Compound 9a (20 g, 79.7 mmol) was dissolved in dry THF (500 mL), and isopropylmagnesium bromide (87.7 mmol, 1 M / THF) was slowly added dropwise under ice-salt bath conditions. After the addition was completed, DMF (11.6 g, 159.4 mmol) was added all at once after continued stirring for 2 h, and water was added dropwise to quench the reaction after continued stirring for 1 h. The organic phases were extracted with ethyl acetate, combined, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (PE: EA = 1: 5) to obtain the title compound 9b (11 g, 55 mmol) with a yield of 69%.
[0340] MS m / z(ESI):202[M+1] + .
[0341] Step 2: 2-(5-bromo-4-methylpyridin-3-yl)-7-chlorobenzo[d] Methyl oxazole-5-carboxylate 9c
[0342] Compound 9b (10 g, 50 mmol) and compound 3-amino-5-chloro-4-hydroxybenzoic acid methyl ester (10 g, 50 mmol) were dissolved in a mixed solvent of EA / EtOH (100 mL / 30 mL), heated to 70°C and stirred for 2 h. After cooling to room temperature, the mixture was concentrated to remove the solvent, DCM (150 mL) was added to dissolve, DDQ (12.5 g, 55 mmol) was added under stirring, and stirring was continued for 1 h. DCM (100 mL) was added to the reaction solution to dilute it, and sodium thiosulfate aqueous solution and sodium bicarbonate aqueous solution were added to quench the reaction. After separation, the aqueous phase was extracted with DCM, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (DCM: EA = 2: 1) to obtain the title compound 9c (6.9 g, 18 mmol) with a yield of 36%.
[0343] MS m / z(ESI):383[M+1] + .
[0344] Step 3 (2-(5-bromo-4-methylpyridin-3-yl)-7-chlorobenzo[d] oxazol-5-yl)methanol 9d
[0345] Compound 9c (10 g, 26 mmol) was dissolved in dry THF (500 mL), cooled to -78 °C in a dry ice acetone bath, and LiAH4 (105 mmol, 1 M / THF) was slowly added dropwise. After the addition was complete, the temperature was slowly raised to -40 °C and stirring was continued for 3 h. The reaction was detected to be complete by TLC. After cooling to -78 °C, water was slowly added dropwise to quench the reaction. The mixture was extracted with ethyl acetate, and the organic phases were combined, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (DCM: MeOH = 15: 1) to give the title compound 9d (5.6 g, 15.8 mmol) in a yield of 60.7%.
[0346] MS m / z(ESI):355[M+1] + .
[0347] Step 4: N-(3-(5-(7-chloro-5-(hydroxymethyl)benzo[d] [2-(4-(2-methylphenyl)-4-(2-oxazol-2-yl)-4-methylpyridin-3-yl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide 9f
[0348] Compound 9d (854 mg, 2.42 mmol), compound 9e (1 g, 2.42 mmol), Pd(dppf)Cl2 (177 mg, 0.242 mmol) and K2CO3 (1 g, 7.26 mmol) were dissolved in dioxane (30 mL) and H2O (6 mL), heated to 90°C and stirred for 3 h under argon protection. After cooling to room temperature, the mixture was separated, the aqueous phase was extracted with ethyl acetate, the organic phases were combined, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography to obtain the title compound 9f (1 g, 1.79 mmol) in a yield of 73.8%.
[0349] MS m / z(ESI):560.3[M+1] + .
[0350] Step 5: N-(3-(5-(7-chloro-5-formylbenzo[d] oxazol-2-yl)-4-methylpyridin-3-yl)-2-methylphenyl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide 9 g
[0351] Compound 9f (240 mg, 0.429 mmol) was dissolved in DCM (20 mL), and DMP (273 mg, 0.643 mmol) was added at room temperature, and stirring was continued for 1 h. Aqueous sodium thiosulfate solution and an aqueous sodium bicarbonate solution were added to quench the reaction, and the liquids were separated. The aqueous phase was extracted with DCM, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 9g (200 mg, 0.358 mmol) in a yield of 83.7%.
[0352] MS m / z(ESI):558.2[M+1] + .
[0353] Step 6: Methyl (R)-1-(((7-chloro-2-(4-methyl-5-(2-methyl-3-(5-methyl-4,5,6,7-thiazolidine)[5,4-c]pyridine-2-carboxamido)phenyl)pyridin-3-yl)benzo[d] (2-(4-((4-oxazol-5-yl)methyl)pyrrolidine-3-carboxylate)9h
[0354] Compound 9g (200 mg, 0.358 mmol) and (R)-pyrrolidine-3-carboxylic acid methyl ester hydrochloride (92.6 mg, 0.559 mmol) were dissolved in dichloromethane (20 mL). The reaction was stirred at room temperature for 30 minutes, and then sodium acetic acid borohydride (379 mg, 1.79 mmol) was added. After stirring overnight at room temperature, the reaction was completed. The reaction solution was quenched with water, extracted three times with dichloromethane, the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the title compound 24h (100 mg, 0.149 mmol) by column chromatography as a white solid in a yield of 41.6%.
[0355] MS m / z(ESI):671.4[M+1] + .
[0356] Step 7 (R)-1-(((7-chloro-2-(4-methyl-5-(2-methyl-3-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)phenyl)pyridin-3-yl)benzo[d] oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid 9
[0357] Compound 24h (100 mg, 0.149 mmol) was dissolved in a mixed solvent of acetonitrile / H2O (5 mL / 5 mL), and LiOH (7.1 mg, 0.298 mmol) was added. After stirring at room temperature for 2 h, the reaction was detected by LCMS. The pH value was adjusted to weak acidity with acetic acid, and pre-HPLC purification was performed to obtain the title compound 9 (40 mg, 0.061 mmol) as a white solid with a yield of 40.9%.
[0358] MS m / z(ESI):657.4[M+1] +
[0359] 1H NMR (400MHz, Methanol-d4) δ9.25 (s, 1H), 8.47 (s, 1H), 7.88 (s, 1H), 7.73 (d, J=8.0Hz, 1H), 7.66 (d , J=1.4Hz, 1H), 7.39 (t, J=7.8Hz, 1H), 7.15 (dd, J=7.6, 1.3Hz, 1H), 4.37 (d, J=13.0Hz, 1H), 4.26 (d, J=13.1Hz, 1H), 3.81(d, J=1.6Hz, 2H), 3.42-3.33(m, 1H), 3.24(m, 2H), 3.18-3.03(m, 2H), 3.00(t, J=5.7Hz, 2H), 2.91 (t, J=5.8Hz, 2H), 2.57 (s, 3H), 2.52 (s, 3H), 2.26 (m, 2H), 2.06 (d, J=3.4Hz, 3H).
[0360] Example 10
[0361] (R)-1-((2-(3′-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) oxazolo[5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid
[0362]
[0363] The title product 10 was prepared by a synthetic method similar to that of Example 4.
[0364] MS m / z(ESI):620.4[M+1] +
[0365] 1H NMR (400MHz, DMSO-d6) δ10.66 (s, 1H), 9.93 (s, 1H), 8.53 (d, J = 2.0Hz, 1H), 8.46 (d, J = 2.0Hz, 1H), 8 .14 (dd, J=8.0, 1.4Hz, 1H), 7.58 (dd, J=8.0, 1.3Hz, 1H), 7.51 (d, J=7.8Hz, 1H), 7.38 (dd, J=7.6, 1. 5Hz, 1H), 7.30 (s, 1H), 7.02 (dd, J=7.7, 1.3Hz, 1H), 4.60 (s, 2H), 4.30 (d, J=85.3Hz, 5H), 3.89 (s, 3 H), 3.85-3.56 (m, 3H), 3.24 (s, 2H), 2.97 (d, J=15.1Hz, 5H), 2.41 (s, 3H), 2.21 (s, 1H), 1.93 (s, 3H).
[0366] Embodiment 11
[0367] (R)-1-(((7-chloro-2-(5-(3-((3-(((((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2-methylphenyl)-4-methylpyridin-3-yl)benzo[d] (oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid trifluoroacetate
[0368]
[0369]
[0370] Step-5-bromo-4-methylnicotinamide 11b
[0371] Compound 11a (20 g, 79.7 mmol) was dissolved in dry THF (500 mL), and isopropylmagnesium bromide (87.7 mmol, 1M / THF) was slowly added dropwise under ice-salt bath conditions. After the addition was completed, DMF (11.6 g, 159.4 mmol) was added all at once after continued stirring for 2 h, and water was added dropwise to quench the reaction after continued stirring for 1 h. The organic phases were extracted with ethyl acetate, combined, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (PE: EA = 1: 5) to obtain the title compound 11b (11 g, 55 mmol) with a yield of 69%.
[0372] MS m / z(ESI):202[M+1] + .
[0373] Step 2: 2-(5-bromo-4-methylpyridin-3-yl)-7-chlorobenzo[d] Methyl oxadiazole-5-carboxylate 11c
[0374] Compound 11b (10 g, 50 mmol) and compound 3-amino-5-chloro-4-hydroxybenzoic acid methyl ester (10 g, 50 mmol) were dissolved in a mixed solvent of EA / EtOH (100 mL / 30 mL), heated to 70°C and stirred for 2 h. After cooling to room temperature, the mixture was concentrated to remove the solvent, DCM (150 mL) was added to dissolve, DDQ (12.5 g, 55 mmol) was added under stirring, and stirring was continued for 1 h. DCM (100 mL) was added to the reaction solution to dilute it, and sodium thiosulfate aqueous solution and sodium bicarbonate aqueous solution were added to quench the reaction. After separation, the aqueous phase was extracted with DCM, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (DCM: EA = 2: 1) to obtain the title compound 11c (6.9 g, 18 mmol) with a yield of 36%.
[0375] MS m / z(ESI):383[M+1] + .
[0376] Step 3 (2-(5-bromo-4-methylpyridin-3-yl)-7-chlorobenzo[d] oxazol-5-yl)methanol 11d
[0377] Compound 11c (10 g, 26 mmol) was dissolved in dry THF (500 mL), cooled to -78°C in a dry ice acetone bath, and LiAH4 (105 mmol, 1 M / THF) was slowly added dropwise. After the addition was complete, the temperature was slowly raised to -40°C and stirring was continued for 3 h. The reaction was detected to be complete by TLC. After cooling to -78°C, water was slowly added dropwise to quench the reaction. The mixture was extracted with ethyl acetate, and the organic phases were combined, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography (DCM: MeOH = 15: 1) to give the title compound 11d (5.6 g, 15.8 mmol) in a yield of 60.7%.
[0378] MS m / z(ESI):355[M+1] + .
[0379] Step 4: 2-(5-bromo-4-methylpyridin-3-yl)-7-chlorobenzo[d] Azole-5-carboxaldehyde 11e
[0380] Compound 26d (1 g, 2.83 mmol) was dissolved in DCM (20 mL), and DMP (1.8 g, 4.24 mmol) was added at room temperature, and stirring was continued for 1 h. Aqueous sodium thiosulfate solution and aqueous sodium bicarbonate solution were added to quench the reaction, and the liquids were separated. The aqueous phase was extracted with DCM, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 11e (900 mg, 2.56 mmol) in a yield of 90.4%.
[0381] MS m / z(ESI):353[M+1] + .
[0382] Step 5 (R)-1-(((2-(5-bromo-4-methylpyridin-3-yl)-7-chlorobenzo[d] (oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid methyl ester 11f
[0383] Compound 11e (200 mg, 0.569 mmol) and (R)-pyrrolidine-3-carboxylic acid methyl ester hydrochloride (188 mg, 1.138 mmol) were dissolved in dichloromethane (20 mL). The reaction was stirred at room temperature for 30 minutes, and then sodium borohydride acetate (603 mg, 2.845 mmol) was added. After stirring at room temperature overnight, the reaction was completed. The reaction solution was quenched with water, extracted three times with dichloromethane, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 11f (150 mg, 0.323 mmol) as a white solid with a yield of 56.7%.
[0384] MS m / z(ESI):466.1[M+1] + .
[0385] Step 6 (R)-1-((7-chloro-2-(5-(3-((3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2-methylphenyl)-4-methylpyridin-3-yl)benzo[d] (oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid 11
[0386] Compound 11f (150 mg, 0.323 mmol), compound 11g (148 mg, 0.323 mmol), Pd(dcydppf)Cl2 (24.4 mg, 0.0323 mmol) and K2CO3 (134 mg, 0.969 mmol) were dissolved in dioxane (15 mL) and H2O (3 mL), heated to 90°C and stirred for 3 h under argon protection. After cooling to room temperature, the mixture was separated, the aqueous phase was extracted with ethyl acetate, the organic phases were combined, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 11 (50 mg, 0.071 mmol) as a white solid in a yield of 22%.
[0387] MS m / z(ESI):704.4[M+1] +
[0388] 1H NMR (400MHz, DMSO-d6) δ10.77-10.04 (m, 4H), 9.45-9.02 (m, 2H), 8.75-8.3 5 (m, 2H), 8.16-7.96 (m, 2H), 7.94 (d, J=6.2Hz, 1H), 7.83-7.73 (m, 1H), 7.46 (t, J=7.8Hz, 1H), 7.20 (dd, J=27.7, 6.9Hz, 2H), 4.82-4.48 (m, 5H), 3.59-3. 29(m, 9H), 2.50(s, 3H), 2.35-2.25(m, 3H), 2.03(s, 3H), 1.90-1.80(m, 1H).
[0389] Example 12
[0390] (R)-1-(((7-chloro-2-(5-(3-(5-((S)-2-hydroxypropyl))-1-methyl-4,5,6,7-tetrahydro-1H-imidazole[4,5-c]pyridine-2-carboxamide)-2-methylphenyl)-4-methylpyridin-3-yl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0391]
[0392] The title product 12 was prepared by a synthetic method similar to that of Example 9.
[0393] MS m / z(ESI):698.4[M+1] +
[0394] 1 H NMR (400MHz, DMSO-d6) δ10.4-10.25 (m, 1H), 10.15-10.0 (m, 1H), 9.94 (s, 1H), 9.23 (s, 1H), 8.5 1 (s, 1H), 8.03 (d, J = 1.5Hz, 1H), 7.79 (d, J = 1.4Hz, 1H), 7.68-7.60 (m, 1H), 7.35 (t, J = 7.8Hz, 1H ), 7.23 (s, 0.5H), 7.13-7.07 (m, 1H), 6.97 (s, 0.5H), 4.60-4.35 (m, 4H), 4.30-4.0 (m, 4H), 3.89 (s, 3H), 3.37-2.89 (m, 8H), 2.45 (s, 3H), 2.45-2.11 (m, 2H), 1.95 (s, 3H), 1.11 (d, J=6.1Hz, 3H).
[0395] Example 13
[0396] (R)-1-(((7-chloro-2-(5-(3-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2-methylphenyl)-4-methylpyridin-3-yl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0397]
[0398] The title product 13 was prepared by a synthetic method similar to that of Example 9.
[0399] MS m / z(ESI):654.4[M+1] +
[0400] 1 H NMR (400MHz, Methanol-d4) δ9.33 (s, 1H), 8.53 (s, 1H), 7.97 (d, J = 1.5Hz, 1H), 7.79 (dd, J = 8.1, 1.3Hz, 1H), 7.73 (d, J = 1.5Hz, 1H), 7.40 (t, J = 7.8Hz, 1H), 7.13(dd, J=7.7, 1.4Hz, 1H), 4.57(s, 2H), 4.50-4.22(m, 2H), 3.98(s, 3H), 3 .86-3.36(m, 8H), 3.10(m, 5H), 2.62(s, 3H), 2.51-2.25(m, 2H), 2.06(s, 3H).
[0401] Embodiment 14
[0402] (R)-1-((2-(3′-(5-((S)-2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazole[4,5-c]pyridine-2-carboxamido)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) oxazolyl[5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid
[0403]
[0404] The title product 14 was prepared by a synthetic method similar to that of Example 4.
[0405] MS m / z(ESI):664.5[M+1] +
[0406] 1H NMR (400MHz, DMSO-d6) δ10.74 (d, J=77.3Hz, 2H), 10.18 (s, 1H), 9.90 (s, 1H), 8.50 (dd, J=29.5, 2.0Hz, 2H), 8.14 ( dd, J=7.9, 1.4Hz, 1H), 7.60 (d, J=8.0Hz, 1H), 7.52 (t, J=7.7Hz, 1H), 7.38 (dd, J=7.7, 1.5Hz, 1H), 7.30 (t, J=7.8H z, 1H), 7.02 (dd, J=7.6, 1.4Hz, 1H), 4.60 (s, 2H), 4.29 (s, 2H), 4.16 (ddd, J=9.3, 6.4, 2.6Hz, 1H), 3.89 (s, 3H), 3. 56 (d, J=60.2Hz, 5H), 3.37-2.90 (m, 6H), 2.41 (s, 3H), 2.19 (d, J=16.6Hz, 2H), 1.93 (s, 3H), 1.11 (d, J=6.1Hz, 3H).
[0407] Embodiment 15
[0408] N-(3-chloro-2-(3-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido))-2-methylphenyl)pyridin-4-yl)-1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 15:
[0409] 1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylic acid lithium 2-8:
[0410]
[0411] 5-(2-(((tert-butyldimethylsilyl)oxy)propyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate 2-11:
[0412]
[0413] The first step is 5-(tert-butyl) 2-methyl 1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-dicarboxylate 2-5
[0414] At -78°C, n-butyl lithium (1.6M, in THF, 58mL, 94.3mmol) was added dropwise to a tetrahydrofuran (50ml) solution of compound 2-4 (14.9g, 0.06mol), and the mixture was stirred at -30°C to -20°C for 30 minutes. The reaction solution was then cooled to -78°C, and methyl chloroformate (11.8g, 126mmol) was added dropwise to the reaction solution. The reaction solution was stirred at -78°C for 2 hours. TLC spot plate showed that the reaction was complete. Saturated ammonium chloride solution was added dropwise to the reaction solution to quench the reaction. The reaction solution was filtered through diatomaceous earth to remove inorganic salts. The filtrate was extracted twice with ethyl acetate (300mL x 2), and the organic phase was dried and concentrated to obtain a crude product. The crude product was separated by silica gel column (petroleum ether: ethyl acetate = 10:1 to 3:1) to obtain a yellow solid compound. The mixture was then slurried with petroleum ether:ethyl acetate = 10:1 to obtain white solid compound 2-5 (3.0 g).
[0415] 1 H NMR (400MHz, CDCl3) δ4.49 (s, 2H), 3.93 (s, 3H), 3.88 (s, 3H), 3.82-3.72 (m, 2H), 2.72-2.62 (m, 2H), 1.46 (s, 9H).
[0416] Step 2 1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylic acid hydrochloride 2-6
[0417] A methanol hydrochloric acid solution (3.0 M, 40 mL) of compound 2-5 (3.0 g, 10 mmol) was stirred at room temperature overnight. LCMS showed that the raw material was completely reacted. The reaction solution was directly spin-dried to obtain a crude compound 2-6 (2.8 g), which was directly used in the next step.
[0418] LCMS (ESI): m / z 196.0 (M+H) + .
[0419] Step 3 1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate 2-7
[0420] Add formaldehyde (0.7 mL, 37 wt.% aqueous solution) to a solution of compound 2-6 (1.3 g, 5.6 mmol) in methanol / dichloroethane (10 mL / 30 mL), and stir the reaction solution at room temperature for 30 minutes. Then add sodium acetate borohydride (3.5 g, 16.8 mmol) to the reaction system, and stir the reaction system at room temperature for 2 hours. The reaction solution is directly concentrated to dryness. The crude product is dispersed in water, extracted with ethyl acetate, and the organic phase is dried over sodium sulfate. The filtrate is concentrated to obtain a crude product, which is separated by silica gel column chromatography (dichloromethane: methanol = 100: 1 to 10: 1) to obtain compound 2-7 (0.90 g, yield: 75%)
[0421] LCMS(ESI): m / z 210.2(M+H)+;
[0422] 1 H NMR (400MHz, CDCl3) δ3.92 (s, 3H), 3.86 (s, 3H), 3.50 (s, 2H), 2.79 (t, J=5.5Hz, 2H), 2.69 (dd, J=8.6, 3.2Hz, 2H), 2.51 (s, 3H).
[0423] Step 4: 1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylic acid lithium 2-8
[0424] Lithium hydroxide monohydrate (199 mg, 4.73 mmol) was added to a methanol (10 ml) solution of compound 2-7 (0.9 g, 4.30 mmol), and the reaction solution was kept at room temperature for 16 hours. The reaction solution was directly spin-dried to obtain yellow solid compound 2-8 (0.95 g, yield: 100%).
[0425] LCMS (ESI): m / z 196.3(M+H)+.
[0426] Step 5: 1-methyl-5-(2-oxopropyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylic acid methyl ester 2-9
[0427] Add bromoacetone (1.5 g, 11.2 mmol) and triethylamine (3.2 mL, 22.4 mmol) to a solution of compound 2-6 (1.3 g, 5.6 mmol) in dioxane (20 mL), and stir the reaction solution at 80 ° C for 2 hours. TLC (dichloromethane: methanol = 10 / 1) shows that the reaction is complete. The reaction solution is directly concentrated to dryness. The concentrate is diluted with water (20 mL) and extracted with ethyl acetate (100 mL x 2). The organic phase is concentrated to obtain a crude product. The crude product is separated by a silica gel column to obtain compound 2-9 (1.5 g).
[0428] LCMS(ESI): m / z 252.2(M+H)+;
[0429] 1H NMR (400MHz, CDCl3) δ3.92 (s, 3H), 3.87 (s, 3H), 3.67 (s, 2H), 3.48 (s, 2H), 2.93 (t, J = 5.7Hz, 2H), 2.73 (t, J = 5.7Hz, 2H), 2.19 (s, 3H).
[0430] Step 6 5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate 2-10
[0431] At 0°C, sodium borohydride (0.23 g, 5.9 mmol) was added in batches to a methanol (30 mL) solution of compound 2-9 (3.0 g, 11.9 mmol), and the reaction solution was stirred at 25°C for 2 hours. LCMS showed that the raw material was complete. Water (30 ml) was added to the reaction solution to quench the reaction, and dichloromethane (100 mL x 2) was used for extraction. The organic phase was dried over anhydrous sodium sulfate, and the filtrate was concentrated to obtain a crude product. The crude product was separated by a silica gel column (dichloromethane: methanol = 100 / 1 to 10 / 1) to obtain a yellow solid compound 2-10 (0.80 g)
[0432] LCMS (ESI): m / z 254.2 (M+H) + .
[0433] Step 7 5-(2-(((tert-butyldimethylsilyl)oxy)propyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylate 2-11
[0434] Add imidazole (0.6 g, 9.3 mmol) to a DMF (15 mL) solution of compound 2-10 (0.8 g, 3.2 mmol) and then add TBSCI (0.9 g, 6.2 mmol). The reaction solution was stirred overnight at room temperature. Water (500 mL) and ethyl acetate (100 mL) were added to the reaction solution, the organic phase was dried over anhydrous sodium sulfate, and the filtrate was dried to obtain a crude product. The crude product was separated by silica gel column chromatography (petroleum ether: ethyl acetate = 1: 1) to obtain a yellow solid compound 2-11 (0.6 g, yield: 50%).
[0435] LCMS (ESI): m / z 368.2 (M+H) + ;
[0436] 1H NMR (400MHz, CDCl3) δ3.92 (d, J=6.0Hz, 1H), 3.86 (s, 3H), 3.80 (s, 3H), 3.51 (s, 2H), 2.83 (dt, J= 7.7, 5.7Hz, 2H), 2.61-2.39 (m, 4H), 1.12 (d, J=6.1Hz, 3H), 0.88-0.78 (m, 9H), 0.01-0.03 (m, 6H).
[0437] Step 8 4,4,5,5-tetramethyl-2-(2-methyl-3-nitrophenyl)-1,3,2-dioxaborane 15-b
[0438] Compound 15-a (5.0 g, 23.3 mmol), biboronic acid pinacol ester (8.9 g, 34.9 mmol), potassium acetate (6.8 g, 69.9 mmol), Pd (dppf) Cl2 (0.8 g, 1.16 mmol) and dioxane (100 mL) were added to the reaction bottle, nitrogen was replaced three times, and the temperature was raised to 100 ° C for 12 hours. Water (20 ml) and ethyl acetate (100 mL x 2) were added to the reaction solution, and the organic phase was dried and concentrated to obtain a crude product. The crude product was separated by silica gel column (ethyl acetate / petroleum ether = 0 to 50%) to obtain compound 15-b (2.3 g, yield 45%).
[0439] Step 9 3-chloro-2-(2-methyl-3-nitrophenyl)pyridin-4-amine 15-c
[0440] Compound 15-b (720 mg, 2.74 mmol), 2-bromo-3-chloropyridin-4-amine (470 mg, 2.28 mmol), potassium carbonate (630 mg, 4.56 mmol), Pd(dppf)Cl2 (210 mg, 0.3 mmol) and dioxane / water (10 mL / 2 ml) were added to the reaction flask, and the temperature was raised to 80°C for 4 hours after nitrogen replacement three times. LCMS showed that the raw materials reacted completely. Water (30 ml) and ethyl acetate (100 mL x2) were added to the reaction solution, and the organic phase was dried and concentrated to obtain a crude product, which was separated by silica gel column chromatography (ethyl acetate / petroleum ether = 0 to 30%) to obtain a brown solid compound 15-c (605 mg, yield: 84%)
[0441] LCMS (ESI): m / z 264.0 (M+H) + .
[0442] Step 10: N-(3-chloro-2-(2-methyl-3-nitrophenyl)pyridin-4-yl)-1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazole [4,5-c] pyridine-2-carboxamide 15-d
[0443] Compound 15-c (150 mg, 0.57 mmol) and 2-8 (144 mg, 0.74 mmol) were dissolved in pyridine (2 mL) / dichloromethane (2 ml), and POCl3 (174 mg, 1.14 mmol) was added dropwise to the above reaction system at room temperature. The reaction solution was kept at room temperature for 3 hours. LCMS showed that the raw material reaction was complete. The reaction solution was concentrated to remove dichloromethane, and then diluted with saturated sodium bicarbonate solution (50 ml), and extracted with ethyl acetate (50 mL x 2). The organic phase was dried over anhydrous sodium sulfate, and the filtrate was concentrated to dryness to obtain a crude product, which was separated by silica gel column chromatography (methanol / dichloromethane = 0% to 10%) to obtain a yellow solid compound 15-d (200 mg, yield: 45%).
[0444] LCMS (ESI): m / z 441.1 (M+H) + .
[0445] Step 11: N-(2-(3-amino-2-methylphenyl)-3-chloropyridin-4-yl)-1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazole [4,5-c] pyridine-2-carboxamide 15-e
[0446] Compound 15-d (200 mg, 0.45 mmol), iron powder (152 mg, 2.72 mmol), saturated ammonium chloride solution (1 ml), and ethanol (4 ml) were added to the reaction bottle in sequence and reacted at 60°C for 3 hours. LCMS showed that the raw materials were completely reacted. The reaction solution was filtered through diatomaceous earth, the filter cake was washed with ethanol (20 ml*3), and the combined filtrate was dried to obtain a crude product, and silica gel column chromatography (methanol / dichloromethane = 0 to 10%) obtained yellow solid compound 15-e (180 mg, yield: 96%).
[0447] LCMS (ESI): m / z 411.1 (M+H) + .
[0448] Step 12 5-(2-((tert-butyldimethylsilyl)oxy)propyl)-N-(3-(3-chloro-4-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamidopyridin-2-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 15-f
[0449] LiHMDS (1.1 ml, 1.17 mmol) was added dropwise to a solution of compound 15-e (160 mg, 0.39 mmol) and 2-11 (286 mg, 0.78 mmol) in anhydrous toluene (6 mL), and the reaction solution was stirred at room temperature overnight. The main point of LCMS detection was the product. Ammonium chloride (10% w, 10 ml) was added dropwise to the reaction solution, and ethyl acetate (20 ml*2) was used for extraction. The organic phase was dried over anhydrous sodium sulfate, and the filtrate was concentrated to dryness to obtain a crude product. The crude product was separated on a preparative plate to obtain a brown solid compound 15-f (180 mg, yield: 62%).
[0450] LCMS (ESI): m / z 746.0 (M+H) + .
[0451] Step 13 N-(3-chloro-2-(3-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido))-2-methylphenyl)pyridin-4-yl)-1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 15
[0452] Compound 15-f (180 mg, 0.24 mmol) was dissolved in ethyl hydrochloride (6 mL) / methanol hydrochloride (2.5 ml), and the reaction solution was stirred at room temperature for 3 hours. LCMS showed that the reaction was complete. The reaction solution was directly spin-dried to obtain a concentrate, which was diluted with methanol (3 ml), and the pH of the methanol solution was adjusted to 7 with triethylamine, and then separated by prep-HPLC (Instrument: Gilson Flow: 25 mL / min Mobile phase A: 0.1% NH4OH in water; Mobile phase B: ACN Gradient: 40%-50%) to obtain a solid product 15 (60.5 mg, yield 40%).
[0453] LCMS (ESI): m / z 632.6 (M+H) + ;
[0454] 1H NMR (400MHz, CDCl3) δ10.07 (s, 1H), 9.18 (s, 1H), 8.52-8.48 (m, 2H), 8.15 (d, J=7.6Hz, 1H), 7.34 (t, J=7.9Hz, 1H), 7.09 (d, J=6.8Hz , 1H), 3.98 (s, 7H), 3.84-3.57 (m, 4H), 3.20-2.72 (m, 8H), 2.70-2.60 (m, 4H), 2.58-2.45 (m, 1H), 2.13 (s, 3H), 1.19 (d, J=6.1Hz, 3H).
[0455] Example 16
[0456] N-(3-(3-chloro-2-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide
[0457]
[0458] Step 1 4-Bromo-3-chloropyridin-2-amine 16b
[0459] Compound 16a (500 mg, 2.38 mmol) was added to aqueous ammonia (28%, 4 mL), heated to 120°C and stirred for 2 h. The aqueous ammonia solution was removed by rotary evaporation to obtain the target compound 16b (475 mg, yield 96%) as a white solid.
[0460] Step 2 3-Chloro-4-(2-methyl-3-nitrophenyl)pyridin-2-amine 16c
[0461] Compound 16b (500 mg, 2.38 mmol), 4,4,5,5-tetramethyl-2-(2-methyl-3-nitrophenyl)-1,3,2-dioxaborolane (711 mg, 2.70 mmol), K2CO3 (657 mg, 4.76 mmol) and Pd(dppf)Cl2 (0.17 g, 0.24 mmol) were added to a mixed solvent of dioxane / H2O (5 ml / 1 mL), and the mixture was heated to 80°C and stirred for 4 h under nitrogen protection. After cooling to room temperature, 20 mL of water was added, and the mixture was extracted with ethyl acetate (40 ml x 2). The organic phases were combined, concentrated, and purified by column chromatography (EA / PE=0%-100%) to obtain the target compound 16c (508 mg, yield 81%) as a brown solid.
[0462] Step 3 N-(3-chloro-4-(2-methyl-3-nitrophenyl)pyridin-2-yl)-1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazole[4,5-c]pyridine-2-carboxamide 16d
[0463] Compound 16c (200 mg, 0.76 mmol), 1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylic acid (192 mg, 0.98 mmol) and phosphorus oxychloride (234 mg, 1.52 mmol) were added to a mixed solvent of pyridine / DCM (2 mL / 2 ml) in sequence, stirred at room temperature for 2 h, and the reaction was completed by LCMS detection. After concentration to remove the solvent, 10 mL of saturated NaHCO3 aqueous solution was added, and ethyl acetate was extracted (50 mL x 2), the organic phases were combined, dried over Na2SO4, and concentrated to obtain a brown oily crude product, which was further purified by silica gel column chromatography (methanol / DCM=0% to 10%) to obtain the target compound 16d (110 mg, yield 32.8%) as a yellow solid.
[0464] MS m / z(ESI):441.1[M+1]+.
[0465] Step 4: N-(4-(3-amino-2-methylphenyl)-3-chloropyridin-2-yl)-1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazole[4,5-c]pyridine-2-carboxamide 16e
[0466] Compound 16d (110 mg, 0.25 mmol), iron powder (84 mg, 1.5 mmol) and saturated NH4Cl aqueous solution (1 mL) were added to EtOH (4 mL), heated to 60°C and stirred for 3 h. The reaction was completed by LCMS. After cooling to room temperature, the reaction solution was filtered through diatomaceous earth, the filtrate was concentrated to remove ethanol and extracted with ethyl acetate (5 ml x 2), the organic phases were combined, dried over Na2SO4, concentrated, and purified by silica gel column chromatography (methanol / DCM=0 to 10%) to obtain the target compound 16e (85 mg, yield 82.9%) as a yellow solid.
[0467] MS m / z(ESI):411.4[M+1] + .
[0468] Step 5 5-(2-((tert-butyldimethylsilyl)oxy)propyl)-N-(3-(3-chloro-2-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazole [4,5-c] pyridine-2-carboxamido pyridin-4-yl)-2-methylphenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo [4,5-c] pyridine-2-carboxamide 16 g
[0469] Compound 16e (85 mg, 0.21 mmol) and compound 16f (114 mg, 0.32 mmol) were dissolved in toluene (2 mL), and LiHMDS (0.62 ml, 0.62 mmol) was added under stirring, and stirred at room temperature overnight. 10% NH4Cl aqueous solution (5 mL) was added to quench the reaction, and ethyl acetate (20 x 2 mL) was used for extraction. The organic phases were combined, dried over Na2SO4, and concentrated. The target compound 16g (110 mg, yield 71%) was purified by pre-TLC as a brown solid.
[0470] MS m / z(ESI):746.4[M+1]+.
[0471] Step 6: N-(3-(3-chloro-2-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide)pyridin-4-yl)-2-methylphenyl)-5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 16
[0472] Compound 16g (110 mg, 0.24 mmol) was dissolved in DCM (2 mL), TBAF (0.5 mL, 1 M in THF) was added, and the mixture was stirred at room temperature for 16 h. The reaction was detected by LCMS, and the solvent was removed by rotary evaporation. The crude product was further purified by prep-HPLC (Instrument: Gilson Flow: 25 mL / min Mobile phase A: 0.1% NH4OH in water Mobile phase B: ACN Gradient: 40%-50%) to obtain target compound 16 (32.7 mg, yield: 35%), purity: 100% (254 nm), white solid.
[0473] MS m / z(ESI):632.6[M+1]+
[0474] 1H NMR (400MHz, CDCl3) δ 10.11 (s, 1H), 9.19 (s, 1H), 8.49 (d, J = 4.8Hz, 1H), 8.15 (d, J = 8.0Hz, 1H), 7.35 (t J=7.8Hz, 1H), 7.01-6.96(m, 2H), 4.01(s, 3H), 4.00(s, 3H), 3.81-3.59(m, 4H), 3.08(m , 1H), 2.95-2.7(m, 7H), 2.63(s, 3H), 2.51(m, 1H), 2.13(s, 3H), 1.21(d, J=6.0Hz, 3H).
[0475] Embodiment 17
[0476] (R)-1-((2-(3′-((3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) (4,5-b]pyridin-5-yl)methyl)pyrrolidine-3-carboxylic acid trifluoroacetate
[0477]
[0478]
[0479] Step 1: 6-amino-5-bromopicolinic acid methyl ester 17b
[0480] Compound 6-aminopicolinic acid methyl ester (50 g, 328.9 mmol) was dissolved in DCM (500 mL), bromine (16.9 mL, 328.9 mmol) was dissolved in DCM (200 mL), and the DCM solution of bromine was slowly added dropwise to the compound solution under an ice bath, and reacted at room temperature for 12 hours after the addition was completed. 150 mL of saturated sodium thiosulfate solution was added, and extracted with dichloromethane three times; the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain the title compound 46b (15.2 g, 65.5 mmol), with a yield of 19.9%.
[0481] Step 2 (2-amino-6-(methoxycarbonyl)pyridin-3-yl)boronic acid 17c
[0482] Compound 6-amino-5-bromopicolinic acid methyl ester 17b (15.2 g, 65.5 mmol) and bis(boronic acid pinacol) (30.8 g, 131 mmol) were dissolved in 1,4-dioxane (100 mL), and [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride (2.39 g, 3.2 mmol) and potassium acetate (192 g, 196.5 mmol) were added, and the mixture was reacted at 100° C. for 6 hours under argon protection. The solid was filtered and the reaction solution was dried to obtain a crude product of the target compound (21.6 g).
[0483] Step 3 6-amino-5-hydroxypicolinic acid methyl ester 17d
[0484] The crude compound (2-amino-6-(methoxycarbonyl)pyridin-3-yl)boronic acid 17c was dissolved in tetrahydrofuran (100 mL), and a 30% aqueous hydrogen peroxide solution (15 mL) was added dropwise under an ice bath and reacted for 3 hours. Sodium sulfite solution was added to quench the reaction, and part of tetrahydrofuran was selected and recrystallized to obtain the target compound methyl 6-amino-5-hydroxypicolinate 17d (8.8 g, 52.1 mmol), with a two-step yield of 79%.
[0485] Step 4: 2-(3-bromo-2-methylphenyl) Methyl oxazolo[4,5-b]pyridine-5-carboxylate 17e
[0486] Compound 6-amino-5-hydroxypicolinic acid methyl ester 17d (8.8 g, 52.1 mmol) and compound 3-bromo-2-methylbenzaldehyde (20.8 g, 104.2 mmol) were dissolved in 80 mL of ethyl acetate: ethanol (v / v=1:1), stirred at 60°C for 6 hours, and after the solvent was dried, dichloromethane (100 mL) was added, and then 2,3-dichloro-5,6-dicyano-p-benzoquinone (17.8 g, 78.5 mmol) was added, and the reaction was carried out at room temperature for 5 hours. Water was added and extracted with dichloromethane 3 times, the organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain the title compound 17e (2.1 g, 6.1 mmol), with a yield of 11%.
[0487] Step 5 (2-(3-bromo-2-methylphenyl) Oxazo[4,5-b]pyridin-5-yl)methanol 17f
[0488] Compound 2-(3-bromo-2-methylphenyl) Methyl oxazolo[4,5-b]pyridine-5-carboxylate 17e (2.1 g, 6.1 mmol) was dissolved in dichloromethane (50 mL), replaced with argon, and diisobutylaluminum hydride (1.86 g, 12.2 mmol) was added dropwise at -78°C, and the temperature was slowly raised to room temperature for 1 hour. Ammonium chloride solution was added and stirred for 10 minutes, water was added, and the mixture was extracted with ethyl acetate three times, dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain the title compound 46f (1.7 g, 5.4 mmol) in a yield of 88%.
[0489] Step 6 2-(3-bromo-2-methylphenyl) Azo[4,5-b]pyridine-5-carboxaldehyde 17g
[0490] Compound (2-(3-bromo-2-methylphenyl) Azo[4,5-b]pyridine-6-methanol 17f (1.7 g, 5.4 mmol) and Dess-Martin reagent (4.5 g, 10.8 mmol) were dissolved in dichloromethane (50 mL) and reacted at room temperature for 3 h. Sodium thiosulfate solution was added and stirred for 10 minutes, extracted with ethyl acetate three times, dried over anhydrous sodium sulfate, concentrated and purified by column chromatography to obtain the title compound 17g (1.57 g, 4.9 mmol) with a yield of 92%.
[0491] Step 7 (R)-1-(((2-(3-bromo-2-methylphenyl) Methyl oxazolo[4,5-b]pyridin-5-yl)methyl)pyrrolidine-3-carboxylate 17h
[0492] Compound 2-(3-bromo-2-methylphenyl) 17g (1.57g, 4.9mmol) of oxazolo[4,5-b]pyridine-6-carboxaldehyde and compound (R)-pyrrolidine-3-carboxylic acid methyl ester hydrochloride (2.4g, 14.7mmol) were dissolved in dichloromethane (50mL) and stirred at room temperature for 1h, and then sodium triacetoxyborohydride (3.1g, 14.7mmol) was added and reacted at room temperature for 12h. Saturated sodium bicarbonate solution was added to quench the reaction, and the mixture was extracted three times with 30mL of dichloromethane, dried with anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain the title compound 17h (1.4g, 3.3mmol) with a yield of 67%.
[0493] Step 8 (E)-5-bromo-3-(2-(dimethylamino)vinyl)-2-cyanopyridine 17j
[0494] Compound 5-bromo-3-methyl-2-cyanopyridine 17i (30 g, 152 mmol) and compound N,N-dimethylformamide dimethyl acetal (36 g, 304 mmol) were dissolved in N,N-dimethylformamide (100 mL) and heated at 140°C for 20 h. The solvent was then dried, ethyl acetate was added, and the sample was purified by column chromatography to obtain the title compound 46j (18 g, 91.3 mmol) with a yield of 60%.
[0495] Step 9 3-Bromo-1,7-naphthyridin-8-(7H)-one 17k
[0496] Compound (E)-5-bromo-3-(2-(dimethylamino)vinyl)-2-cyanopyridine 17j (18 g, 91.3 mmol) was dissolved in ethanol (80 mL), and hydrobromic acid (23 g, 285 mmol) was added and heated to 90°C for 6 h. The yellow solid was filtered out and the hydrobromic acid was washed off with sodium bicarbonate solution to obtain the title compound (6.8 g, 30.2 mmol) with a yield of 33.1%.
[0497] Step 10 3-Bromo-8-chloro-1,7-naphthyridine 17l
[0498] The compound 3-bromo-1,7-naphthyridin-8-(7H)-one (6.8 g, 30.2 mmol) was dissolved in phosphorus oxychloride (50 mL) and heated at 110°C for 3 h. The reaction solution was dropped into ice water and extracted with ethyl acetate three times. The organic phase was dried over anhydrous sodium sulfate and purified by column chromatography to obtain the title compound 171 (4.1 g, 16.8 mmol) with a yield of 55.6%.
[0499] Step 11: 8-chloro-3-vinyl-1,7-naphthyridine 17m
[0500] To compound 171 (2 g, 8.23 mmol) and 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane (1.394 g, 9.053 mmol) in 1,4-dioxane / water (v / v=4 / 1) (50 mL), [1,1′-bis(diphenylphosphino)ferrocene]palladium dichloride (601 mg, 0.823 mmol) and sodium carbonate (1.744 g, 16.46 mmol) were added, and the reaction was completed after 4 hours at 110° C. under argon protection. The reaction solution was added with water and extracted with ethyl acetate three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 17m (800 mg, 4.21 mmol) in a yield of 51%.
[0501] Step 12 8-Chloro-1,7-naphthyridine-3-carbaldehyde 17n
[0502] Under an ice bath, potassium osmate (31 mg, 0.0842 mmol) was added to 1,4-dioxane / water (v / v=4 / 1) (50 mL) of compound 8-chloro-3-vinyl-1,7-naphthyridine 17m (800 mg, 4.21 mmol), and sodium periodate (1.8 g, 8.42 mmol) was added after stirring for 1 hour. After warming to room temperature, the mixture was stirred overnight to complete the reaction. The reaction solution was extracted with ethyl acetate three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 17n (600 mg, 3.125 mmol) with a yield of 74%.
[0503] Step 13 (R)-1-((8-chloro-1,7-naphthyridin-3-yl)methyl)pyrrolidin-3-ol 17o
[0504] Compound 8-chloro-1,7-naphthyridine-3-carboxaldehyde 17n (800 mg, 4.16 mmol) and (R)-pyrrolidin-3-ol (1.0879 g, 12.513 mmol) were dissolved in dichloromethane (40 mL), acetic acid (250 mg, 0.416 mmol) was added, and sodium triethoxyborohydride (2.65 mg, 12.513 mmol) was added after stirring for 1 hour. After stirring overnight at room temperature, the reaction was completed. Saturated sodium bicarbonate and ethyl acetate were added to the reaction solution for extraction, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 17o (0.72 g, 2.737 mmol) with a yield of 65%.
[0505] Step 14 (R)-1-((8-((2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-di (boryl)phenyl)amino)-1,7-naphthyridin-3-yl)methyl)pyrrolidin-3-ol 17p
[0506] Compound (R)-1-((8-chloro-1,7-naphthyridin-3-yl)methyl)pyrrolidin-3-ol 17o (700 mg, 2.661 mmol) and compound 2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)aniline (682 mg, 2.927 mmol) were dissolved in isopropanol (40 mL), HCl / dioxane (1.33 mL, 5.322 mmol) was added, heated to 95 ° C. and stirred for 4 hours, then dried by rotation, saturated sodium bicarbonate and ethyl acetate were added for extraction, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography to give the title compound 17p (0.65 g, 1.41 mmol) in a yield of 53%.
[0507] Step 15 (R)-1-((2-(3′-((3-(((R)-3-hydroxypyrrolidin-1-yl)methyl)-1,7-naphthyridin-8-yl)amino)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) Oxazo[4,5-b]pyridin-5-yl)methyl)pyrrolidine-3-carboxylic acid trifluoroacetate 17
[0508] Compound (R)-1-((8-((2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-di (((2-(3-bromo-2-methylphenyl)-1-( ... Methyl oxazolo[4,5-b]pyridinyl-5-yl)methyl)pyrrolidine-3-carboxylate 17h (30 mg, 0.07 mmol) was dissolved in tert-butyl alcohol / water (v / v=2 / 1) (10 mL), 1,1′-bis(di-cyclohexylphosphino)ferrocenepalladium dichloride (5.1 mg, 0.007 mmol) and cesium carbonate (45 mg, 0.14 mmol) were added, and the mixture was heated at 100° C. for 2 h. The solid was filtered out, the solvent was dried, and the target compound 17 (24.6 mg, 0.031 mmol) was obtained by preparative HPLC with a yield of 45%.
[0509] MS m / z(ESI):669.7[M+H] + .
[0510] 1H NMR (400MHz, Methanol-d4) δ9.17 (d, J=2.1Hz, 1H), 8.56 (d, J=2.1Hz, 1H), 8.27 (dd, J=7.9, 1.6Hz, 1H), 8.22 (d, J=8 .3Hz, 1H), 7.68-7.62 (m, 2H), 7.57 (s, 1H), 7.54 (d, J=7.6Hz, 2H), 7.48 (dd, J=7.6, 1.5Hz, 1H), 7.36 (d, J=7.5Hz, 1H ), 7.30 (d, J=7.0Hz, 1H), 4.81 (s, 1H), 4.78-4.71 (m, 3H), 4.60 (s, 1H), 3.78-3.59 (m, 3H), 3.57-3.48 (m, 2H), 3.46 ( q, J=1.6Hz, 1H), 3.40 (dd, J=16.0, 6.5Hz, 2H), 2.58 (s, 3H), 2.49-2.23 (m, 4H), 2.14 (d, J=5.5Hz, 1H), 2.08 (s, 3H).
[0511] Embodiment 18
[0512] (R)-1-((2-(2,2′-dimethyl-3′-(4,5,6,7-tetrahydrothiazolidine[5,4-c]pyridine-2-carboxamido)-[1,1′-biphenyl]-3-yl) Azolyl[5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid trifluoroacetate
[0513]
[0514] The title product 18 was prepared by a synthetic method similar to that of Example 4.
[0515] 1 H NMR (400MHz, DMSO-d6) δ10.41 (s, 1H), 9.43 (s, 2H), 8.53 (d, J=2.0Hz, 1H), 8.46 (d, J= 2.0Hz, 1H), 8.14 (dd, J=8.0, 1.4Hz, 1H), 7.57-7.45 (m, 2H), 7.38 (dd, J=7.6, 1.5Hz, 1 H), 7.32 (t, J=7.7Hz, 1H), 7.07 (dd, J=7.7, 1.3Hz, 1H), 4.59 (s, 2H), 4.51 (s, 2H), 3.5 1(s, 4H), 3.23(s, 2H), 3.09(t, J=6.2Hz, 2H), 2.40(s, 3H), 2.20(s, 1H), 1.92(s, 3H).
[0516] MS m / z(ESI):609.4[M+H] + .
[0517] Embodiment 19
[0518] (R)-1-(((7-chloro-2-(4-methyl-5-(2-methyl-3-(1-methyl-4,5,6,7-tetrahydro-1H-imidazole)[4,5-c]pyridine-2-carboxamido)phenyl)pyridin-3-yl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0519]
[0520] The title product 19 was prepared by a synthetic method similar to that of Example 9.
[0521] MS m / z(ESI):640.4[M+1] +
[0522] 1 H 7 .13(dd, J=7.7, 1.4Hz, 1H), 4.57(s, 2H), 4.26(s, 2H), 3.98(s, 3H), 3.76-3.3 6(m, 7H), 3.03(t, J=6.0Hz, 2H), 2.62(s, 3H), 2.53-2.27(m, 2H), 2.06(s, 3H).
[0523] Embodiment 20
[0524] (R)-1-(((7-chloro-2-(3-(5-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-4-methylpyridin-3-yl)-2-methylphenyl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid methyl ester
[0525]
[0526] The title product 20 was prepared by a synthetic method similar to that of Example 8.
[0527] MS m / z(ESI):668[M+1] +
[0528] 1 H NMR (400MHz, DMSO-d6+D2O) δ8.63 (s, 1H), 8.15 (s, 1H), 8.12 (dd, J=7.9, 1.4Hz, 1H), 7.6 8(d, J=1.5Hz, 1H), 7.53 (t, J=7.7Hz, 1H), 7.45 (d, J=1.4Hz, 1H), 7.39 (dd, J=7.6, 1.5Hz, 1H), 3.81 (s, 3H), 3.72-3.61 (m, 2H), 3.55 (s, 3H), 3.33 (s, 2H), 3.00 (d, J=1.9Hz, 1H), 2. 73-2.56 (m, 7H), 2.50 (dd, J=7.1, 2.2Hz, 3H), 2.35 (d, J=10.2Hz, 7H), 2.04-1.85 (m, 6H).
[0529] Embodiment 21
[0530] (R)-1-(((7-chloro-2-(3-(5-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-4-methylpyridin-3-yl)-2-methylphenyl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0531]
[0532] First step (R)-1-(((7-chloro-2-(3-(5-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-4-methylpyridin-3-yl)-2-methylphenyl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0533] Take a single-mouth bottle, add compound 21a (60 mg, 0.089 mmol), MeOH / H2O (1:1, 6.0 mL) and LiOH (6.2 mg, 0.27 mmol) in sequence, and react at room temperature for 3 h. The system is neutralized with 1N HCl solution to neutrality. Purify by reverse phase column chromatography (C18, MeCN / H2O) to obtain the target compound 21 (55 mg) as a white solid.
[0534] MS m / z(ESI):654[M+1] +
[0535] 1H NMR (400MHz, DMSO-d6+D2O) δ8.72 (s, 1H), 8.30 (s, 1H), 8.16 (dd, J=8.0, 1.4Hz, 1H), 7.96 (d, J=1.5Hz, 1H), 7.71 (d, J=1.5Hz, 1H), 7.57 (t, J=7.8Hz, 1H) , 7.44 (dd, J=7.6, 1.4Hz, 1H), 4.43 (d, J=41.6Hz, 3H), 4.18 (s, 1H), 3.85 (s, 3H), 3.61-3.08(m, 7H), 2.93(s, 5H), 2.37(s, 3H), 2.21(s, 2H), 2.01(s, 3H).
[0536] Embodiment 22
[0537] (R)-1-((2-(3′-(5-((S)-2-hydroxypropyl)4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) oxazolyl[5,4-b]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid
[0538]
[0539] The title product 22 was prepared by a synthetic method similar to that of Example 4.
[0540] MS m / z(ESI):667.5[M+1] +
[0541] 1 H NMR (400MHz, Methanol-d4) δ8.53 (d, J=2.0Hz, 1H), 8.38 (d, J=2.1Hz, 1H), 8.20 (dd, J=7.9, 1.5H z, 1H), 7.63 (dd, J=8.1, 1.3Hz, 1H), 7.49 (t, J=7.7Hz, 1H), 7.44-7.32 (m, 2H), 7.10 (dd, J=7.6, 1 .3Hz, 1H), 4.76 (s, 2H), 4.65 (s, 2H), 4.32-4.22 (m, 1H), 3.80 (s, 2H), 3.46 (d, J=33.7Hz, 5H), 3. 40-3.30 (m, 3H), 3.23 (dd, J=13.0, 10.5Hz, 1H), 2.49 (s, 5H), 2.03 (s, 3H), 1.26 (d, J=6.2Hz, 3H).
[0542] Embodiment 23
[0543] (S)-N-(5-(2-chloro-3-(1-methyl-5-(oxetan-3-yl)-4,5,6,7-tetrahydro-1H-imidazole [4,5-c] pyridine-2-carboxamide)phenyl)-4-methylpyridin-3-yl)-5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazole [4,5-c] pyridine-2-carboxamide
[0544]
[0545]
[0546] First step 5-(tert-Butyloxycarbonyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxylic acid 23b
[0547] Compound 23a (5 g, 21.097 mmol) was dissolved in tetrahydrofuran (50 mL), and n-butyl lithium (12.65 mL, 31.645 mmol) was slowly added dropwise at -78 ° C under argon protection. After stirring for 1 hour, 10 grams of dry ice was added. After stirring for 2 hours, the temperature was slowly raised to room temperature, and then a dilute hydrochloric acid solution in dioxane was added to adjust the pH value to a weak acid. The reaction solution was spin-dried and purified by column chromatography to obtain the title compound 23b (2.6 g, 9.252 mmol) with a yield of 43.8%.
[0548] MS m / z(ESI):282.1[M+1] + .
[0549] Step 2 5-(tert-Butyl) 2-methyl-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-2,5-dicarboxylate 23c
[0550] Compound 23b (3 g, 10.676 mmol) was dissolved in N, N-dimethylformamide (30 mL), potassium bicarbonate (3.202 g, 32.028 mmol) and iodomethane (3.032 g, 21.352 mmol) were added, and the reaction was completed after 24 h at room temperature. The reaction solution was washed with water, extracted three times with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 23c (1 g, 3.389 mmol) with a yield of 31.36%.
[0551] MS m / z(ESI):296.2[M+H] + .
[0552] Step 3 2-((3-bromo-2-chlorophenyl)carbamoyl)tert-butyl-1-methyl-1,4,6,7-tetrahydro-5H-imidazo[4,5-c]pyridine-5-carboxylate 23d
[0553] Compound 23c (1 g, 3.389 mmol) and 3-bromo-2-chloroaniline (1.047 g, 5.08 mmol) were dissolved in toluene (30 mL), and HMDSLi (6.778 mL, 6.778 mmol) was added at room temperature. After 24 h of reaction, the reaction was completed. The reaction solution was washed with water, extracted three times with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 23d (1.1 g, 2.345 mmol) with a yield of 69.6%.
[0554] MS m / z(ESI):471.2[M+H] + .
[0555] Step 4: N-(3-bromo-2-chlorophenyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 23e
[0556] Compound 23d (500 mg, 1.066 mmol) was dissolved in dichloromethane (10 mL), and trifluoroacetic acid (10 mL) was added, and then stirred at room temperature for 1 h to complete the reaction. The reaction solution was concentrated to obtain the title compound 23e (520 mg, 1.066 mmol) with a yield of 100%. The crude product was directly used for the next step.
[0557] MS m / z(ESI)371.1[M+1] + .
[0558] Step 5: N-(3-bromo-2-chlorophenyl)-1-methyl-5-( 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 23f
[0559] Compound 23e (520 mg, 1.066 mmol) was dissolved in dichloromethane (80 mL), and then 3-oxetanone (231 mg, 3.21 mmol) was added. Sodium borohydride (680 mg, 3.21 mmol) was added under the protection of ice bath argon, and the mixture was slowly heated to room temperature and stirred overnight to complete the reaction. The reaction solution was quenched with dilute hydrochloric acid and then saturated sodium bicarbonate was added, extracted three times with ethyl acetate, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to give the title compound 23f (360 mg, 0.845 mmol) by column chromatography with a yield of 74%.
[0560] MS m / z(ESI):427.1[M+H] + .
[0561] Step 6: N-(3-(5-amino-4-methylpyridin-3-yl)-2-chlorophenyl)-1-methyl-5-( 23 g of 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide
[0562] Compound 23f (150 mg, 0.3529 mmol) and 5-amino-4-methylpyridin-3-yl)boric acid (107 mg, 0.7058 mmol) were dissolved in 1,4-dioxane (3 mL) and water (1 mL), and ditri-tert-butylphosphine palladium (18 mg, 0.03529 mmol) and potassium carbonate (96 mg, 0.7058 mmol) were added. After heating at 100 ° C. and stirring for 5 h under the protection of argon, the reaction was completed. Water and ethyl acetate were added to the reaction solution for extraction, and the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 23g (80 mg, 0.176 mmol) with a yield of 50%.
[0563] MS m / z(ESI):453.3[M+1] +
[0564] Step 7 (S)-5-(2-((tert-butyldimethylsilyl)oxy)propyl)-N-)5-(2-chloro-3-(1-methyl-5-(oxetan-3-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl-4-methylpyridin-3-yl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide 23i
[0565] Compound 23g (80 mg, 0.176 mmol) and 23h (97 mg, 0.265 mmol) were dissolved in toluene (10 mL), and HMDSLi (0.35 mL, 0.35 mmol) was added at room temperature. After 24 h of reaction, the reaction was completed. The reaction solution was washed with water, extracted three times with dichloromethane, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 23i (88 mg, 0.111 mmol) with a yield of 63.3%.
[0566] MS m / z(ESI):788.5[M+H] + .
[0567] Step 8 (S)-N-(5-(2-chloro-3-(1-methyl-5-(oxetan-3-yl)-4,5,6,7-tetrahydro-1H-imidazole [4,5-c] pyridine-2-carboxamide)phenyl)-4-methylpyridin-3-yl)-5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazole [4,5-c] pyridine-2-carboxamide 23
[0568] Compound 23i (88 mg, 0.111 mmol) was dissolved in tetrahydrofuran (5 mL), and then TBAF / THF solution (0.35 mL, 0.35 mmol) was added, and the mixture was stirred at room temperature overnight to complete the reaction. The reaction solution was added with water and extracted with ethyl acetate three times, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by Prep-HPLC to obtain the title compound 23 (25 mg, 0.037 mmol) with a yield of 33%.
[0569] MS m / z(ESI):674.4[M+1] +
[0570] 1 H NMR (400MHz, DMSO-d6) δ10.10 (s, 1H), 9.90 (s, 1H), 8.62 (s, 1H), 8.33 (dd, J=8.3, 1.5Hz, 1H), 8.18 (s, 1H), 7.47 (t, J=7.9Hz, 1H), 7.11 (dd, J=7.6, 1.6Hz, 1H), 4.55 (t, J=6.5Hz, 2H), 4.46 (t, J=6.1H z, 2H), 3.85 (d, J=13.9Hz, 7H), 3.66 (t, J=6.4Hz, 2H), 3.19-3.09 (m, 1H), 2.99 (s, 2H), 2.84-2.52 ( m, 7H), 1.97 (s, 3H), 1.53 (s, 1H), 1.32-1.21 (m, 1H), 1.05 (d, J=6.1Hz, 3H), 0.90 (t, J=7.4Hz, 1H).
[0571] Embodiment 24
[0572] (S)-N-(2-chloro-3-(5-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide)-4-methylpyridin-3-yl)phenyl)-5-isopropyl-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide
[0573]
[0574] MS m / z(ESI):660.5[M+1] +
[0575] 1 H NMR (400MHz, DMSO-d6) δ9.97 (d, J=64.2Hz, 2H), 8.64 (s, 1H), 8.34 (dd, J=8.3, 1.6Hz, 1H), 8.17 (s, 1H) , 7.47 (t, J=7.9Hz, 1H), 7.10 (dd, J=7.6, 1.5Hz, 1H), 4.34 (d, J=4.0Hz, 1H), 3.84 (d, J=13.5Hz, 6H), 3. 45 (d, J=9.3Hz, 4H), 2.94-2.86 (m, 1H), 2.76 (dt, J=19.4, 5.7Hz, 4H), 2.62 (t, J=7.6Hz, 4H), 2.52 (q, J =1.9Hz, 1H), 2.43 (d, J = 6.9Hz, 1H), 2.37 (dd, J = 12.5, 5.4Hz, 1H), 1.98 (s, 3H), 1.02 (t, J = 6.7Hz, 9H).
[0576] Embodiment 25
[0577] (R)-1-(((7-cyano-2-(4-methyl-5-(2-methyl-3-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)phenyl)pyridin-3-yl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0578]
[0579] First step N-(3-bromo-2-methylphenyl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide 25c
[0580] Compound 25a (3.0 g, 15.13 mmol) and 25b (2.82 g, 15.13 mmol) were dissolved in DMF (25 mL), and HATU (8.62 g, 22.7 mmol) and DIPEA (3.9 g, 30.26 mmol) were added in sequence, and the reaction was allowed to react overnight at room temperature. The reaction solution was diluted with EA (100 mL), washed once with water, washed several times with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 25c (2.2 g, 5.33 mmol) as a light yellow solid in a yield of 35.2%.
[0581] MS m / z(ESI):368.1[M+1] + .
[0582] Step 2 5-Methyl-N-(2-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-4,5,6,7-tetrahydrothiazo[5,4-c]pyridine-2-carboxamide 25d
[0583] Compound 25b (5 g, 13.65 mmol) and biboronic acid pinacol ester (10.4 g, 40.95 mmol) were dissolved in 1,4-dioxane (100 mL), and [1,1′-bis(diphenylphosphino)ferrocene] palladium dichloride (998 mg, 1.365 mmol) and potassium acetate (6.69 g, 68.25 mmol) were added. The mixture was heated to 100° C. and stirred for 4 h under the protection of nitrogen. After cooling to room temperature, water and ethyl acetate were added and stirred for 2 min. The mixture was separated, the aqueous phase was extracted with EA, the organic phase was washed with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 25d (3 g, 7.26 mmol) in a yield of 54.8%.
[0584] MS m / z(ESI):414.3[M+1] + .
[0585] Step 3 N-(3-(5-(7-chloro-5-(hydroxymethyl)benzo[d] [2-(4-(2-methylphenyl)-4-(2-(2-methyl-2-thiazolo[5,4-c]pyridine)-2-carboxamide 25f]
[0586] Compound 25d (1 g, 2.42 mmol), compound 25e (854 mg, 2.42 mmol), Pd(dcydppf)Cl2 (177 mg, 0.242 mmol) and K2CO3 (1 g, 7.26 mmol) were dissolved in dioxane (30 mL) and H2O (6 mL), and heated to 90°C under argon protection and stirred for 3 h. After cooling to room temperature, the mixture was separated, the aqueous phase was extracted with ethyl acetate, the organic phases were combined, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 25f (500 mg, 0.892 mmol) as a white solid in a yield of 36.9%.
[0587] MS m / z(ESI):560.3[M+1] + .
[0588] Step 4: N-(3-(5-(7-cyano-5-(hydroxymethyl)benzo[d] 25 g of oxazol-2-yl)-4-methylpyridin-3-yl)-2-methylphenyl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide
[0589] Compound 25f (500 mg, 0.893 mmol), Zn(CN)2 (209 mg, 1.785 mmol) and t-Bu-X-phos-PdCl2 (141 mg, 0.179 mmol) were added to a mixed solvent of dioxane (25 mL) / H2O (25 mL), heated to 90°C and stirred for 4 h under argon protection. After cooling to room temperature, the mixture was separated, the aqueous phase was extracted with ethyl acetate, the organic phases were combined, washed once with saturated brine, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 25g (350 mg, 0.892 mmol) as a white solid in a yield of 63.6%.
[0590] MS m / z(ESI):551.3[M+1] + .
[0591] Step 5: N-(3-(5-(7-cyano-5-formylbenzo[d] oxazol-2-yl]-4-methylpyridin-3-yl)-2-methylphenyl)-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide 25h
[0592] Compound 25g (380 mg, 0.690 mmol) was dissolved in DCM (25 mL), and DMP (380 mg, 0.897 mmol) was added at room temperature, and stirring was continued for 1 h. The reaction was completed by LCMS. Aqueous sodium thiosulfate solution and aqueous sodium bicarbonate solution were added to quench the reaction, and the liquids were separated. The aqueous phase was extracted with DCM, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 25h (300 mg, 0.655 mmol) in a yield of 94.5%.
[0593] MS m / z(ESI):549.3[M+1] + .
[0594] Step 6: Methyl (R)-1-(((7-cyano-2-(4-methyl-5-(2-methyl-3-(5-methyl-4,5,6,7-thiazolidine)[5,4-c]pyridine-2-carboxamido)phenyl)pyridin-3-yl)benzo[d] (oxazol-5-yl)methyl)pyrrolidine-3-carboxylate 25i
[0595] Compound 25h (150 mg, 0.273 mmol) and (R)-pyrrolidine-3-carboxylic acid methyl ester hydrochloride (91 mg, 0.547 mmol) were dissolved in dichloromethane (20 mL), and the reaction was stirred at room temperature for 30 minutes, and then sodium acetic acid borohydride (289 mg, 1.367 mmol) was added, and the reaction was completed by LCMS detection after stirring overnight at room temperature. The reaction solution was quenched with water, extracted three times with dichloromethane, and the organic phases were combined, washed with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the title compound 25i (120 mg, 0.181 mmol) by column chromatography as a yellow foamy solid in a yield of 66.4%.
[0596] MS m / z(ESI):662.5[M+1] + .
[0597] Step 7 (R)-1-(((7-cyano-2-(4-methyl-5-(2-methyl-3-(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamido)phenyl)pyridin-3-yl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0598] Compound 25i (100 mg, 0.151 mmol) was added to a mixed solvent of MeCN (4 mL) / H2O (4 mL), and LiOH (4 mg, 0.167 mmol) was added under stirring, and stirred at room temperature for 2 h. LCMS detected that the reaction was complete, and the pH of the reaction solution was adjusted to neutral with dilute HCl, and pre-HPLC separation and purification were performed to obtain the target compound 25 (65 mg, 0.0742 mmol) with a yield of 49.2%.
[0599] MS m / z(ESI):648.5[M+1] +
[0600] 1 H NMR (400MHz, DMSO-d6) δ10.49 (s, 3H), 9.25 (s, 1H), 8.53 (s, 1H), 8.40 (d, J= 1.5Hz, 1H), 8.14 (d, J=1.5Hz, 1H), 7.52 (dd, J=8.1, 1.3Hz, 1H), 7.37 (t, J=7 .8Hz, 1H), 7.16 (dd, J=7.6, 1.3Hz, 1H), 4.67 (d, J=79.8Hz, 4H), 3.79-3.10 ( m, 9H), 2.97 (s, 3H), 2.45 (d, J=1.8Hz, 3H), 2.38-2.12 (m, 2H), 1.94 (s, 3H).
[0601] Embodiment 26
[0602] N-(5-(2-chloro-3-(5-((S)-2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)phenyl)-4-methylpyridin-3-yl)-5-((S)-2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide
[0603]
[0604] The title product 26 was prepared by a synthetic method similar to that of Example 23.
[0605] MS m / z(ESI):676.5[M+1] +
[0606] 1 H NMR (400MHz, Methanol-d4) δ9.52 (s, 1H), 8.65 (s, 1H), 8.47 (d, J = 8.2Hz, 1H), 7.58 (t, J = 7.9Hz, 1H), 7.31 (d, J = 7.4Hz, 1H), 4.58 (s, 2H), 4 .35 (d, J=49.6Hz, 4H), 4.03 (d, J=1.9Hz, 8H), 3.65 (s, 2H), 3.39 (s, 2H), 3.20 (d, J=26.1Hz, 6H), 2.44 (s, 3H), 1.25 (dd, J=6.1, 1.9Hz, 6H).
[0607] Embodiment 27
[0608] N-(2-Chloro-3-(5-(5-ethyl-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-4-methylpyridin-3-yl)phenyl)-5-ethyl-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamide
[0609]
[0610] The title product 27 was prepared by a synthetic method similar to that of Example 23.
[0611] MS m / z(ESI):616.5[M+1] +
[0612] 1H NMR (400MHz, DMSO-d6) δ10.25 (s, 3H), 9.94 (s, 1H), 8.64 (s, 1H), 8.31-8.17 (m, 2H), 7.50 (t, J=7.9Hz, 1H), 7.16 (dd, J=7.6, 1.6Hz, 1H), 4.41 (d, J=14.7 Hz, 2H), 4.20 (s, 2H), 3.90 (d, J=16.6Hz, 6H), 3.79 (s, 2H), 3.39 (s, 2H), 3.2 8 (s, 4H), 2.98 (d, J = 15.2Hz, 4H), 1.99 (s, 3H), 1.28 (td, J = 7.2, 4.1Hz, 6H).
[0613] Embodiment 28
[0614] (R)-1-((2-(3′-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2)2′-dimethyl-[1,1′-biphenyl]-3-yl) oxazolo[5,4-c]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid
[0615]
[0616]
[0617] Step 1: 4-amino-5-iodopicolinic acid methyl ester
[0618] Compound 28a (25 g, 0.16 mol) and NIS (44 g, 0.19 mol) were dissolved in DCM (200 mL) and heated under reflux for 8 h. Water was added to the reaction solution, filtered, and the filter cake was washed twice with DCM. The filtrates were combined, washed several times with saturated brine, concentrated, and purified by column chromatography to obtain the title compound 28b (18 g, yield 40%).
[0619] MS m / z(ESI):278[M+1] + .
[0620] Step 2 4-(3-bromo-2-methylbenzamide)-5-iodopicolinic acid methyl ester
[0621] Compound 28c (28 g, 0.13 mol) was dissolved in dichloromethane (300 mL), oxalyl chloride (68 g, 0.54 mol) was added under ice bath, and the reaction was stirred at room temperature for 2 h. The reaction solution was evaporated to dryness, and 100 ml of dichloromethane was added to dissolve for later use. In another three-necked flask, compound 28b (30 g, 0.11 mol) was dissolved in dichloromethane (300 mL), DIPEA (56 g, 0.43 mol) was added, and the above-mentioned solution was added dropwise. After the addition, the solution was stirred at room temperature overnight. Water was added and stirred to separate the liquids. The organic phase was concentrated and passed through a flash column to obtain the title compound 28d (25 g, yield 48%).
[0622] MS m / z(ESI):477[M+1] + .
[0623] Step 3 2-(3-bromo-2-methylphenyl) Methyl oxazolo[5,4-c]pyridine-6-carboxylate
[0624] Compound 28d (1.0, 2.1 mmol), phenanthroline (72 mg, 0.4 mmol), CuI (76 mg, 0.4 mmol) and Cs2CO3 (1.4 g, 4.2 mmol) were added to dioxane (10 mL) and stirred at 110°C for 16 h. The mixture was filtered and the filter cake was slurried with DCM / MeOH and filtered. The filtrates were combined, concentrated and purified by column chromatography to give 28e (2 g, yield 13%).
[0625] MS m / z(ESI):347[M+1] + .
[0626] Step 4 (2-(3-bromo-2-methylphenyl) oxazolo[5,4-c]pyridin-6-yl)methanol
[0627] Compound 28e (2 g, 5.7 mmol) was dissolved in DCM / THF (10 mL), cooled to -70 °C, and DIBAL-H (11 mL, 11.4 mmol) was added. The temperature was naturally raised to room temperature and stirred for 1 h. Then, aqueous potassium sodium tartrate solution was added and stirred to separate the layers. The organic phase was concentrated and passed through a flash column to obtain 28f (1.8 g, yield 90%) as a white solid.
[0628] MS m / z(ESI):321[M+1] + .
[0629] Step 5 2-(3-bromo-2-methylphenyl) Azo[5,4-c]pyridine-6-carboxaldehyde
[0630] Compound 28f (2 g, 6.26 mmol) was dissolved in dichloromethane (50 mL), and DMP (4 g, 9.40 mmol) was added, and the mixture was reacted at room temperature for 2 h. Na2SO3 aqueous solution and NaHCO3 aqueous solution were added to the reaction solution, and the layers were separated by stirring. The organic phase was dried over anhydrous sodium sulfate, concentrated, and purified by column chromatography to obtain compound 28g (1.8 g, yield 90%).
[0631] MS m / z(ESI):320.9[M+1] + .
[0632] Step 6 (R)-1-(((2-(3-bromo-2-methylphenyl) oxazolo[5,4-c]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid methyl ester
[0633] Compound 28g (2 g, 6.3 mmol) and compound 28h (1.6 g, 12.6 mmol) were dissolved in dichloromethane (50 mL) and methanol (2 mL), sodium acetyl borohydride (1.3 g, 6.3 mmol) was added, and the reaction was completed after stirring overnight at room temperature. The reaction solution was quenched with NaHCO3 aqueous solution, extracted three times with dichloromethane, and the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 28i (1 g, 36%).
[0634] MS m / z(ESI):430[M+1] + .
[0635] Step 7 (R)-1-((2-(3′-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) oxazolo[5,4-c]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid methyl ester
[0636] Compound 28i (251 mg, 0.58 mmol) and compound 28j (240 mg, 0.58 mmol), Pd(dppf)Cl2 (84 mg, 0.12 mmol), K2CO3 (165 mg, 1.2 mmol) were dissolved in dioxane (20 mL) and water (2 mL), replaced with N2, and reacted at 110°C for 4 h. Water was added to the reaction solution, extracted three times with dichloromethane, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, concentrated, and purified by column chromatography to obtain the title compound 28k (150 mg, 40%), which was directly used in the next step.
[0637] MS m / z(ESI):634.4[M+1] + .
[0638] Step 8 (R)-1-((2-(3′-(1,5-dimethyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2)2′-dimethyl-[1,1′-biphenyl]-3-yl) oxazolo[5,4-c]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid
[0639] Compound 28k (150 mg, 0.24 mmol) was dissolved in acetonitrile (5 mL), water (2 ml) was added, and the mixture was stirred at room temperature for 2 h. The pH value was adjusted to weak acidity with acetic acid, and the title compound 28 (120 mg, yield 80%) was prepared and purified.
[0640] MS m / z(ESI):620.5[M+1] +
[0641] 1 H NMR (400MHz, DMSO-d6) δ10.59 (s, 2H), 9.95 (s, 1H), 9.24 (d, J=1.0Hz, 1H), 8.17 (dd, J=7.9, 1.4Hz, 1H) , 8.05 (d, J=1.0Hz, 1H), 7.60-7.49 (m, 2H), 7.40 (dd, J=7.7, 1.5Hz, 1H), 7.30 (t, J=7.8Hz, 1H), 7.02 (dd , J=7.7, 1.4Hz, 1H), 4.66 (s, 2H), 4.41 (d, J=11.4Hz, 1H), 4.18 (s, 1H), 3.88 (s, 3H), 3.72 (d, J=11.0Hz, 1H), 3.42 (d, J=99.0Hz, 6H), 2.96 (d, J=18.3Hz, 6H), 2.41 (s, 3H), 2.21 (d, J=51.9Hz, 2H), 1.92 (s, 3H).
[0642] Embodiment 29
[0643] (R)-1-((2-(3′-(5-(2-hydroxypropyl)-1-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-2-carboxamido)-2,2′-dimethyl-[1,1′-biphenyl]-3-yl) oxazolyl[5,4-c]pyridin-6-yl)methyl)pyrrolidine-3-carboxylic acid
[0644]
[0645] The title product 29 was prepared by a synthetic method similar to that of Example 28.
[0646] MS m / z(ESI):664.5[M+1] +
[0647] 1 H NMR (400MHz, DMSO-d6) δ10.58 (s, 1H), 10.11 (s, 1H), 9.91 (s, 1H), 9.24 (d, J = 1.0Hz, 1H), 8.17 (dd, J = 7.9, 1.5Hz, 1H), 8.05 (d, J=1.0Hz, 1H), 7.59 (d, J=8.0Hz, 1H), 7.54 (t, J=7.7Hz, 1H), 7.40 (dd, J=7.7, 1.5Hz, 1H), 7.30 (t, J= 7.8Hz, 1H), 7.02 (dd, J=7.6, 1.4Hz, 1H), 4.66 (s, 2H), 4.33 (dd, J=55.6, 15.0Hz, 5H), 4.13 (d, J=9.2Hz, 2H), 3.88 (s, 3H), 3.26 (s, 3H), 3.11-2.96 (m, 3H), 2.41 (s, 3H), 2.21 (d, J = 51.1Hz, 2H), 1.92 (s, 3H), 1.10 (d, J = 6.1Hz, 3H).
[0648] Embodiment 30
[0649] (R)-1-(((7-chloro-2-(3-(5-(5-((S)-2-hydroxypropyl))-1-methyl-4,5,6,7-tetrahydro-1H-imidazole[4,5-c]pyridine-2-carboxamido)-4-methylpyridin-3-yl)-2-methylphenyl)benzo[d] (2-(2-oxazol-5-yl)methyl)pyrrolidine-3-carboxylic acid
[0650]
[0651] The title product 30 was prepared by a synthetic method similar to that of Example 8.
[0652] MS m / z(ESI):698[M+1] +
[0653] 1H NMR (400MHz, DMSO-d6+D2O) δ10.94 (s, 1H), 10.52 (s, 1H), 10.35 (dd, J=8.0, 1.4Hz, 1H), 10.15 (d, J=1 .4Hz, 1H), 9.90 (d, J=1.4Hz, 1H), 9.76 (t, J=7.8Hz, 1H), 9.63 (dd, J=7.7, 1.4Hz, 1H), 6.56 (d, J=87.5 Hz, 4H), 6.29 (ddd, J=9.9, 6.4, 2.8Hz, 1H), 6.03 (s, 3H), 5.68 (d, J=53.8Hz, 5H), 5.41 (d, J=14.5Hz, 2 H), 5.31-5.06 (m, 4H), 4.56 (s, 3H), 4.38 (d, J=12.8Hz, 2H), 4.26-4.18 (m, 3H), 3.28 (d, J=6.1Hz, 3H).
[0654] Biological activity test
[0655] Experiment 1: Determination of in vitro activity of the inventor's programmed death receptor ligand (PD-L1) small molecule compound
[0656] 1. Purpose of the experiment
[0657] In this experiment, the blocking effect of the compounds of the present invention on the binding of human programmed death receptor (PD-1) and human programmed death receptor ligand (PD-L1) was tested by homogeneous time-resolved fluorescence (HTRF), and the in vitro activity of the compounds was evaluated based on the half inhibitory concentration (IC50).
[0658] 2. Experimental Methods
[0659] 2.1 Preparation of experimental compounds
[0660] Compounds 1-30 and BMS202 used in this experiment were dissolved in dimethyl sulfoxide (DMSO) to prepare a 10 millimolar (mM) stock solution. The highest concentration of the test compound was 0.1 micromol per liter (μM), and the test compound was diluted 10 times, with a total of 6 concentration gradients, and duplicate wells.
[0661] 2.2 Experimental Procedure
[0662] According to the instruction manual of Cisbio's human programmed death receptor (PD-1) and human programmed death receptor ligand (PD-L1) binding detection kit (Cat. No.: 64ICP01PEG), 2 μL of compound diluted in gradient concentration, 4 μL of human programmed death receptor (PD-1) protein and 4 μL of human programmed death receptor ligand (PD-L1) protein were added to 384 wells respectively, and the mixture was allowed to react at room temperature for 15 minutes. Then, 5 μL of lanthanide europium (Eu) labeled anti-human immunoglobulin Fc fusion protein antibody (anti-hFc) and 5 μL of modified allophycocyanin (XL665) labeled anti-histidine antibody (anti-His) were added respectively. The total reaction system was 20 μL. The mixture was allowed to react at room temperature for 2 hours. Finally, the fluorescence values at 665 nm and 620 nm were read on an ELISA reader. Homogeneous time-resolved fluorescence (HTRF) rate is (665nm) / (620nm)×10 4 Graphpad Prism 7.0 software was used to calculate the half inhibitory concentration (IC50) value.
[0663] 2.3 Experimental Results
[0664] The compounds of the present invention have a significant inhibitory effect on the binding of human programmed death receptor (PD-1) and human programmed death receptor ligand (PD-L1), and the half-inhibitory concentration (IC50) of their in vitro activity is less than 10nM, and the IC50 value of the positive drug BMS202 is 16.61 nM.
[0665] Conclusion: The compounds of the present invention have significant inhibitory activity on the binding of human programmed death receptor (PD-1) and human programmed death receptor ligand (PD-L1), and the inhibitory activity is significantly higher than that of BMS202.
[0666] Experiment 2: Pharmacokinetics of the compounds of the present invention in rats
[0667] 1. Experimental purpose:
[0668] Taking SD rats as an example, the drug concentrations in plasma at different times after oral and intravenous administration of the compounds of Examples 1, 5, 6, 8, 12, 13, 15, 18, 19, 22, 25, 27 and 29 were determined by liquid chromatography-tandem mass spectrometry (LS / MS / MS) and the relevant pharmacokinetic parameters were calculated to evaluate the pharmacokinetic properties of the compounds of the embodiments of the present invention in rats.
[0669] 2. Experimental plan
[0670] 2.1 Trial Drugs
[0671] Compound of Example 1, Compound of Example 5, Compound of Example 6, Compound of Example 8, Compound of Example 12, Compound of Example 13, Compound of Example 15, Compound of Example 18, Compound of Example 19, Compound of Example 22, Compound of Example 25, Compound of Example 27, Compound of Example 29
[0672] 2.2 Experimental animals
[0673] Healthy adult SD rats, SPF grade, male, were purchased from Shanghai Xipu-Bikai Experimental Animal Co., Ltd., license number SCXK (Shanghai) 2018-0006, animal certificate number: 20180006006321.
[0674] 2.3 Drug preparation
[0675] A certain amount of compound was weighed, dissolved in 5% dimethyl sulfoxide (DMSO), vortexed and sonicated, and 0.5% sodium carboxymethyl cellulose (CMC-Na) was added and sonicated to prepare a uniform solution.
[0676] 2.4 Administration
[0677] The specific administration was carried out according to the experimental plan, and the details are shown in Table 2.
[0678] Table 2. Pharmacokinetic study protocol in rats
[0679]
[0680]
[0681] 2.5 Blood collection time and sample processing
[0682] Blood was collected through the eye socket before administration and 5 minutes, 15 minutes, 0.5 hours, 1 hour, 2 hours, 4 hours, 6 hours, 8 hours and 24 hours after administration. 0.2 milliliters (mL) of blood was collected each time, placed in an anticoagulant tube, mixed, and stored in a -20°C refrigerator for later use.
[0683] 3. Sample testing and data analysis
[0684] Liquid chromatography-tandem mass spectrometry (LS / MS / MS) was used to determine the content of the compounds in rat whole blood.
[0685] The pharmacokinetic parameters of the compounds after administration were calculated using the non-compartmental model of WinNonLin5.3 software.
[0686] 4. Test results
[0687] The pharmacokinetic parameters of the compounds of the present invention after administration are shown in the following Table 3. As shown in Table 3, the compounds of the present invention have good metabolic characteristics and bioavailability.
[0688] Table 3. Pharmacokinetic parameters of the compounds of the present invention
[0689]
[0690] Experiment 3: In vivo efficacy test of the compounds of the present invention in mice
[0691] 1. Dosage regimen
[0692] Under sterile conditions, the mouse colon cancer MC38-hPD-L1 in the logarithmic growth phase was digested into single cells and then transplanted subcutaneously on the right side of the back of C57BL / 6 mice. Each mouse was inoculated with 1×10 6 Cells, volume 100 μL, after inoculation, when the tumor grows to 100 cubic millimeters (mm 3 ), the mice were randomly divided into 9 groups, 8 mice in each group for drug efficacy experiments, the positive control was human programmed death receptor ligand (PD-L1) antibody, and the negative control group was given an equal amount of solvent. The specific design is shown in Table 4.
[0693] Table 4: In vivo efficacy experimental plan of compounds
[0694]
[0695] 2. Experimental Animals
[0696] C57BL / 6 mice, SPF grade, 6-8 weeks old, female, were purchased from Beijing Weitonglihua Laboratory Animal Technology Co., Ltd., license number SCXK (Shanghai) 2017-0011, animal certificate number: 20170011003865.
[0697] 3. Experimental drugs
[0698] Example compound 4, Example compound 9, Example compound 11, Example compound 15, Example compound 23, Example compound 27, Example compound 30.
[0699] 4. Preparation of drugs
[0700] An appropriate amount of compound was weighed, dissolved in 5% dimethyl sulfoxide (DMSO), vortexed and sonicated, and 0.5% sodium carboxymethyl cellulose (CMC-Na) was added and sonicated to prepare a 5 mg / mL solution.
[0701] 5. Drug administration
[0702] The specific administration is carried out according to the administration plan.
[0703] 6. Experimental results and conclusions
[0704] The tumor growth inhibition rates of Example Compound 4, Example Compound 9, Example Compound 11, Example Compound 15, Example Compound 23, Example Compound 27 and Example Compound 30 at a dosage concentration of 50 mg / kg were 82%, 78%, 85%, 86%, 81%, 80% and 79%, respectively, while the tumor growth inhibition rate of PD-L1 antibody at a dosage concentration of 5 mg / kg was only 65%, indicating that Example Compound 4, Example Compound 9, Example Compound 11, Example Compound 15, Example Compound 23, Example Compound 27 and Example Compound 30 of the present invention have more effective tumor growth inhibition effects in the mouse colon cancer MC38-hPD-L1 model than the control group human programmed death receptor ligand (PD-L1) antibody.
[0705] Experiment 4: Acute toxicity test of the compounds of the present invention in mice
[0706] 1. Purpose of the experiment
[0707] The purpose of this experiment is to test the toxic effects of compounds in mice.
[0708] 2. Experimental Animals
[0709] ICR mice, SPF grade, 6-8 weeks old, half male and half female, were purchased from Shanghai Xipu-Bikai Experimental Animal Co., Ltd., license number SCXK (Shanghai) 2018-0006, animal certificate number: 20180006010983.
[0710] 3. Experimental drugs
[0711] Example compound 2, Example compound 4, Example compound 9, Example compound 11, Example compound 13, Example compound 19, Example compound 21, Example compound 24, Example compound 26, Example compound 30.
[0712] 4. Experimental Methods
[0713] ICR mice were given a single dose of different doses of the compound and observed for 14 consecutive days, and the animal deaths, poisoning reactions, weight changes, diet, appearance, behavior, etc. were recorded. At the end point, the animals were dissected, and the organs were removed for histopathological examination.
[0714] 5. Experimental results and conclusions
[0715] The median lethal dose (LD50) of Example Compound 2, Example Compound 4, Example Compound 9, Example Compound 11, Example Compound 13, Example Compound 19, Example Compound 21, Example Compound 24, Example Compound 26 and Example Compound 30 were all greater than 1000 milligrams per kilogram (mg / kg). Compared with the mice in the control group, the mice in the drug administration group showed no abnormalities in body weight and behavior within 14 days from the date of administration, indicating that Example Compound 2, Example Compound 4, Example Compound 9, Example Compound 11, Example Compound 13, Example Compound 19, Example Compound 21, Example Compound 24, Example Compound 26 and Example Compound 30 of the present invention are safe.
[0716] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. A compound of formula I, in X 1 N, X 2 CH, X 3 CH; R 0 -NH-C(O)-R 6 or -NH-R 6 ; R 1 is -CH3; R 3 is -Cl or -CH3; R 4 is -H or -CH3; R 5 -NH-C(O)-R 7 、-NH-R 7 , R 6 for R e is -H, -CH3, -CH2CH3, -CH(CH3)2, -CH2CH(CH3)OH or R f is -CH3, -CH2CH3, -CH(CH3)2, -CH2CH(CH3)OH, -CH2CH(OH)CH3, 2. A compound selected from:
3. A method for preparing a compound of formula I as defined in claim 1, wherein the compound of formula I is prepared by the following scheme: Compound (III-1) reacts with the corresponding arylamine (III-2) under alkaline conditions in the presence of a condensing agent to obtain compound (III-3); compound (III-3) is reduced with a reducing agent and then reacted with the corresponding acid (III-5) under alkaline conditions in the presence of a condensing agent to obtain compound (I).
4. Use of the compound according to claim 1 or 2 in the preparation of a medicament for preventing, alleviating or treating cancer, infection or autoimmune disease.
5. The use according to claim 4, wherein the cancer is one or more of brain tumor, nasopharyngeal cancer, lung cancer, breast cancer, cervical cancer, esophageal cancer, gastric cancer, liver cancer, colorectal cancer, blood cancer and bone cancer.
6. Use of the compound according to claim 1 or 2 in the preparation of a PD-1 inhibitor and / or a PD-L1 inhibitor.
7. A pharmaceutical composition comprising a therapeutically and / or prophylactically effective amount of the compound according to claim 1 or 2, and a pharmaceutically acceptable carrier and / or diluent.
